WO2010031190A1 - Culture medium for myoblasts, precursors thereof and derivatives thereof - Google Patents
Culture medium for myoblasts, precursors thereof and derivatives thereof Download PDFInfo
- Publication number
- WO2010031190A1 WO2010031190A1 PCT/CA2009/001342 CA2009001342W WO2010031190A1 WO 2010031190 A1 WO2010031190 A1 WO 2010031190A1 CA 2009001342 W CA2009001342 W CA 2009001342W WO 2010031190 A1 WO2010031190 A1 WO 2010031190A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- culture medium
- medium
- cells
- myogenic lineage
- Prior art date
Links
- 239000001963 growth medium Substances 0.000 title claims description 87
- 210000003098 myoblast Anatomy 0.000 title claims description 86
- 239000002243 precursor Substances 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims description 218
- 239000002609 medium Substances 0.000 claims description 76
- 230000001114 myogenic effect Effects 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 55
- 102000004127 Cytokines Human genes 0.000 claims description 47
- 108090000695 Cytokines Proteins 0.000 claims description 47
- 230000003387 muscular Effects 0.000 claims description 40
- 230000035755 proliferation Effects 0.000 claims description 30
- 210000002966 serum Anatomy 0.000 claims description 25
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
- 230000007812 deficiency Effects 0.000 claims description 22
- 239000007640 basal medium Substances 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 20
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims description 18
- 239000003102 growth factor Substances 0.000 claims description 17
- 239000013589 supplement Substances 0.000 claims description 15
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 14
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 14
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 14
- 239000004017 serum-free culture medium Substances 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 13
- 210000000663 muscle cell Anatomy 0.000 claims description 13
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 12
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 12
- 102000004877 Insulin Human genes 0.000 claims description 12
- 108090001061 Insulin Proteins 0.000 claims description 12
- 229940125396 insulin Drugs 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 11
- -1 IL-14 Proteins 0.000 claims description 10
- 102000015696 Interleukins Human genes 0.000 claims description 10
- 108010063738 Interleukins Proteins 0.000 claims description 10
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 10
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- 229940116977 epidermal growth factor Drugs 0.000 claims description 9
- 210000005070 sphincter Anatomy 0.000 claims description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 238000001574 biopsy Methods 0.000 claims description 7
- 210000000107 myocyte Anatomy 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 102000013361 fetuin Human genes 0.000 claims description 6
- 108060002885 fetuin Proteins 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 102100030703 Interleukin-22 Human genes 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 229940114079 arachidonic acid Drugs 0.000 claims description 4
- 235000021342 arachidonic acid Nutrition 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 229940082569 selenite Drugs 0.000 claims description 4
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 3
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 3
- 102000017761 Interleukin-33 Human genes 0.000 claims description 3
- 108010067003 Interleukin-33 Proteins 0.000 claims description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 102000004338 Transferrin Human genes 0.000 claims description 3
- 108090000901 Transferrin Proteins 0.000 claims description 3
- 239000012574 advanced DMEM Substances 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 229940107161 cholesterol Drugs 0.000 claims description 3
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 3
- 229960002969 oleic acid Drugs 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims description 2
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims description 2
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 2
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 claims description 2
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 claims description 2
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 102000003815 Interleukin-11 Human genes 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 102000049772 Interleukin-16 Human genes 0.000 claims description 2
- 101800003050 Interleukin-16 Proteins 0.000 claims description 2
- 102000013691 Interleukin-17 Human genes 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 102000003810 Interleukin-18 Human genes 0.000 claims description 2
- 108090000171 Interleukin-18 Proteins 0.000 claims description 2
- 102100039879 Interleukin-19 Human genes 0.000 claims description 2
- 108050009288 Interleukin-19 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010066979 Interleukin-27 Proteins 0.000 claims description 2
- 102000000646 Interleukin-3 Human genes 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 101710181613 Interleukin-31 Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000000585 Interleukin-9 Human genes 0.000 claims description 2
- 108010002335 Interleukin-9 Proteins 0.000 claims description 2
- 102000004114 interleukin 20 Human genes 0.000 claims description 2
- 108090000681 interleukin 20 Proteins 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 108010074109 interleukin-22 Proteins 0.000 claims description 2
- 102000003898 interleukin-24 Human genes 0.000 claims description 2
- 108090000237 interleukin-24 Proteins 0.000 claims description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 101150081880 FGF1 gene Proteins 0.000 claims 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 description 29
- 102100036912 Desmin Human genes 0.000 description 20
- 108010044052 Desmin Proteins 0.000 description 20
- 210000005045 desmin Anatomy 0.000 description 20
- 210000003205 muscle Anatomy 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000000654 additive Substances 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 12
- 210000001087 myotubule Anatomy 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000003693 Hedgehog Proteins Human genes 0.000 description 5
- 108090000031 Hedgehog Proteins Proteins 0.000 description 5
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 5
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000009758 senescence Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010069091 Dystrophin Proteins 0.000 description 4
- 102000001039 Dystrophin Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100032970 Myogenin Human genes 0.000 description 4
- 108010056785 Myogenin Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 2
- 101100351033 Mus musculus Pax7 gene Proteins 0.000 description 2
- 102100038380 Myogenic factor 5 Human genes 0.000 description 2
- 101710099061 Myogenic factor 5 Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229930185229 antidesmin Natural products 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000003365 myofibril Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000022379 skeletal muscle tissue development Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010002947 Connectin Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000973497 Mus musculus E3 ubiquitin-protein ligase MIB2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102100034434 Nebulin Human genes 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100026260 Titin Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000003130 muscle precursor cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 108010084677 myogenic factor 6 Proteins 0.000 description 1
- 108010059725 myosin-binding protein C Proteins 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 108010054130 nebulin Proteins 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000034272 protein filaments Human genes 0.000 description 1
- 108091005974 protein filaments Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
Definitions
- Duchenne muscular dystrophy (DMD), with a prevalence of 1 boy out of 3500, is the most widely spread genetic disease (Voisin, 2004). This disease is characterized by the progressive weakening of muscles, resulting in muscular necrosis and fibrosis (Emery, 2003).
- An essential protein for muscle fibers stability, dystrophin is missing or defective in muscle fibers of DMD patients.
- Dystrophin is a 427-kDa protein which connects the actin cytoskeleton to the cellular membrane (Bogdanovich et al. 2004). The function of this protein is to maintain the stability of the cellular membrane in order to support the stresses induced during muscular contractions (Carpenter et al. 1990).
- the absence of dystrophin increases the vulnerability of muscle fibers during their contraction. Consequently, constant muscular repair will be necessary, which will result in the premature senescence of myoblasts.
- cellular therapy a therapy under development to counter DMD, has shown significant therapeutic effect in several studies in mice (Chen, Li et al. 1992) and humans (Gussoni et al. 1992; Huard et al. 1992; Huard et al. 1994; Skuk et al. 2006; Skuk et al. 2007).
- This curative approach is regarded as a promising treatment (Skuk and Tremblay, 2000).
- cellular therapy consists in injecting human myoblasts in the muscles of the DMD patients.
- the healthy myoblasts fuse to muscle fibers of the patients and partially restore the expression of dystrophin. This expression increases the strength of the treated muscle and restores at least partially their functionality, hence improving significantly the patient's quality of life.
- myoblast injections are also used for the treatment of myocardial infarction and for urethral sphincter insufficiency.
- the grafts of myoblasts significantly improve the contractility as well as the viability of cardiac tissues and allows 41 % restoration of the normal sphincter contractility (Yiou et al. 2004; Kahn, 2006).
- the nutritional needs of in vitro cultured cells comprise a vast range of molecules, of which several are found in a basal medium, which contains the essential components necessary to the cellular metabolism and osmotic balance maintenance: salts, amino-acids, vitamins, sugars, lipids, trace elements, antioxidants and pH buffer (Ham and McKeehan 1979; Butler, 1991 ; Mather and Barnes 1998; Davis, 2002; Naomoto et al. 2005).
- the basal medium must be selected considering its compatibility with the type of cells to be cultured, as well as its performance with regards to predetermined responses of interest. The role of the basal medium can therefore either be to support proliferation, differentiation or quiescence of a given cell population (Zimmerman et al. 2000).
- Basal media known to support myoblast expansion are DMEM, F12, RPMI1640 (Goto et al. 1999) and MCDB120 (Ham et al. 1988).
- the medium generally used to culture myoblasts in vitro is MCDB120 supplemented with 15% fetal bovine serum (FBS), 10 ng/ml basic fibroblast growth factor (bFGF), 0.39 ⁇ g/ml dexamethasone and 0.5 mg/ml bovine serum albumin (BSA).
- FBS fetal bovine serum
- bFGF basic fibroblast growth factor
- BSA bovine serum albumin
- Serum is an additive which allows the nonspecific proliferation of a vast range of cell types. It is prepared from plasma, the liquid fraction of blood, from which clotting factors were removed.
- the principal sources of sera for cell culture are bovine fetal blood (FBS), calf (CS), horse (HS) or human. FBS is the most widely used.
- Serum can also be contaminated by viruses, bacteria and prions (Jayme et al. 1988; Freshney, 2000). It is therefore advantageous to replace serum by a mixture of defined components that would not present similar problems. Serum- free media allow a better control of cell proliferation and differentiation and reduce the risk of contamination (Zimmerman et al. 2000). However, serum-free media are much more specific than serum-containing media, often only supporting the growth or differentiation of the cell type for which it has been developed. The corollary of this is therefore that most cell lineage will require the development of their own serum-free medium.
- the present invention relates to a culture medium for cells of the myogenic lineage that is free of serum and/or any other undefined supplement.
- This serum-free culture medium allows the cells to proliferate at a rate that is similar to the one of cells cultured in a serum-containing medium.
- the present invention also relates to a method for culturing cells in vitro where the serum- free medium is used. The use of the cells cultured in the serum-free media in cellular therapy for muscle-associated conditions is also contemplated.
- the present invention provides a culture medium for a cell of the myogenic lineage.
- the culture medium comprises a basal medium and a cytokine or a combination of cytokines.
- the culture medium is free of serum and allows the proliferation of the cell of the myogenic lineage at a similar rate than another cell of the myogenic lineage cultured in a standard medium containing serum.
- the cell of the myogenic lineage is at least one of a muscular stem cell, a myoblast and a myoblast-derived cell.
- the muscular stem cell can differentiate into a myoblast.
- the myoblast-derived cell is at least one of a muscle cell, a satellite cell and a myocyte.
- the cell of the myogenic lineage is derived from a biopsy, is a mammalian cell and/or is a human cell.
- the basal medium is at least one of Dulbecco's modified Eagles's medium (DMEM), advanced DMEM, BiogroTM, SkGM ® , Ham's F10, Ham's F12, Iscove's modified Dulbecco's medium, neurobasal medium, RPMI 1640 and MCDB120 medium.
- the basal medium is a combination of Ham's F12, RPMI 1640 and MCDB120 and, in a further embodiment, the proportion of Ham's F12, RPMI 1640 and MCDB120 is about 1 :1 :1.
- the cytokine is a human cytokine. In still another embodiment, the cytokine is a recombinant cytokine. In yet another embodiment, the cytokine is at least one of a growth factor (GF) and an interleukin. In still another embodiment, the growth factor is at least one of a fibroblast growth factor (FGF), an epidermal growth factor (EGF) and an insulin-like growth factor (IGF). In yet another embodiment, the concentration of FGF in the culture medium is between about 1 and 20 ng/ml. In an embodiment, the FGF is at least one of FGF-1 , FGF-2, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8 and FGF-9.
- GF growth factor
- FGF fibroblast growth factor
- EGF epidermal growth factor
- IGF insulin-like growth factor
- the concentration of FGF in the culture medium is between about 1 and 20 ng/ml. In an embodiment, the FGF is at least one of FGF-1
- the concentration of EGF in the culture medium is between about 1 and 20 ng/ml. In yet another embodiment, the concentration of IGF in the culture medium is between about 1 and 50 ng/ml. In an embodiment, the IGF is at least one of IGF-1 and IGF-2. In still another embodiment, the concentration of interleukin in the culture medium is between about 0.1 to 20 ng/ml.
- the interleukin is at least one of IL-I , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 , IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21 , IL-22, IL- 23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31 , IL-32 and IL-33.
- the culture medium further comprises a supplement and, in yet another embodiment, the supplement is at least one of: i) a combination of insulin (at a concentration, for example, of 0.5 mg/ml), transferrin (at a concentration, for example, of 5 mg/ml) and selenite (at a concentration, for example, of 0.52 ⁇ g/ml) (ITS); ii) B27 medium supplement; iii) a combination of dexamethasone, insulin, EGF, fetuin and albumin; and iv) a combination of dexamethasone, bFGF, albumin and insulin.
- the concentration of ITS in the culture medium is between about 0.5 and 2.5% v/v.
- the culture medium further comprises a lipid and, in still another embodiment, the lipid is at least one of arachidonic acid, cholesterol, DL- ⁇ -tocopherol acetate, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitoleic acid, palmitic acid and stearic acid. In still another embodiment, the concentration of the lipid in the culture medium is between about 0.5 and 2.5% v/v.
- the present invention provides an in vitro method of culturing a cell of the myogenic lineage.
- the method can comprise contacting the cell of the myogenic lineage with the culture medium described herein thereby culturing said cell.
- the cell of the myogenic lineage is at least one of a muscular stem cell, a myoblast and a myoblast-derived cell.
- the muscular stem cell can differentiate into a myoblast.
- the myoblast-derived cell is at least one of a muscle cell, a satellite cell and a myocyte.
- the method is performed for at least an hour, for at least a day, for at least a week or for at least a month.
- the method reduces the lag phase of the cell of the myogenic lineage with respect to the lag phase of a cell of the myogenic lineage cultured in another serum-free media.
- the method enables the long term expansion of the cell of the myogenic lineage.
- the initial concentration of the cell of the myogenic lineage in the culture medium is 10 000 cells/mL.
- the method enables the cell of the myogenic lineage to retain its ability to form a myotube.
- the present invention provides a method of treating or alleviating a muscular deficiency in a subject in need thereof.
- the method comprises contacting a cell of the myogenic lineage with the culture medium described herein ; and implanting the cell previously obtained in the subject; thereby treating or alleviating the muscular deficiency in the subject.
- the method comprises providing a cell of the myogenic lineage cultured by the method described herein and implanting the cultured cell obtained in the subject; thereby treating or alleviating the muscular- associated condition in the subject.
- the subject is a human.
- the muscular-deficiency is at least one of Duchenne muscular dystrophy, myocardial infarction, urethral sphincter insufficiency.
- the present invention provides the use of a cell of the myogenic lineage cultured in the culture medium described herein or prepared by the method described herein for the treatment or the alleviation of symptoms of a muscular deficiency in a subject.
- the subject is a human.
- the muscular deficiency is associated with at least one of Duchenne muscular dystrophy, myocardial infarction, urethral sphincter insufficiency.
- the present invention provides a cell of the myogenic lineage cultured in the culture medium described herein or prepared by the method described herein for the treatment or the alleviation of symptoms of a muscular deficiency in a subject.
- the subject is a human.
- the muscular deficiency is associated with at least one of Duchenne muscular dystrophy, myocardial infarction, urethral sphincter insufficiency.
- Fig. 1 compares the expansion of human myoblasts cultured in various media (0, standard (STD) medium; D, first generation serum-free medium (MBa); ⁇ , MBa supplemented with macrophage conditioned medium (MCM); x, MBa supplemented with interleukin 1 ⁇ (IL-1 ⁇ ); * , MBa supplemented with IL1 ⁇ ; o, MBa supplemented with calpeptine; I , MBa supplemented with B27 supplement, N2 supplement and sonic hedgehog (ShH) during the course of a nine-day culture.
- STD standard
- MCM macrophage conditioned medium
- x MBa supplemented with interleukin 1 ⁇
- * MBa supplemented with IL1 ⁇
- o MBa supplemented with calpeptine
- I MBa supplemented with B27 supplement, N2 supplement and sonic hedgehog (ShH) during the course of a nine-day culture.
- Fig. 2 compares the expansion of human myoblasts cultured in various media (o, optimized serum-free medium (LOBSFM); o, Lonza serum-free medium composed of the basal medium SKBM ® supplemented with BulletkitTM additives; ⁇ , standard medium; x, SKBM ® medium supplemented with the LOBSFM additives for five days.
- LOBSFM optimized serum-free medium
- o Lonza serum-free medium composed of the basal medium SKBM ® supplemented with BulletkitTM additives
- ⁇ standard medium
- x SKBM ® medium supplemented with the LOBSFM additives for five days.
- Fig. 3 compares the long-term expansion of BB13 cells in various media (0, standard medium, duplicates 1 and 2; G, LOBSFM, duplicates 1 and 2) expressed in expansion folds in function of time (days).
- Fig. 4 shows micrographs of immunostained cells that proliferated in LOBSFM (A to F) and STD medium (G to I) with cell nucleic represented as dots; desmin represented as elongated structures in panels A-C, E and I, myosin heavy chain represented as elongated structures in panels D, F, G, H.
- the cells were cultured either for one week (D and G), two weeks (A), four weeks (B, E 1 H) or six weeks (C, F, I).
- Cells in boxes D to H were fixed and immunostained after a three-day incubation in the differentiation medium.
- Fig. 5 illustrates the proportion of desmin-expressing cells from independent experiments for (A) BB13 cells in STD medium(O) or LOBSFM (D); and (B) H49 (o) or H51 ( ⁇ ) cells in STD medium (solid line) or LOBSFM (broken line).
- Fig. 6 shows flow cytometry results of a four weeks myoblast culture.
- A BB13 cellular counts against intensity for NCAM + cells cultured in LOBSFM (98,8%) or STD medium (96,9%).
- B H49 cellular counts against intensity for cells cultured in LOBSFM (left curve) or standard medium (right curve) as indicated by the arrows.
- C Side scatter against forward scatter for cells cultured in standard medium.
- D Side scatter against forward scatter for cells cultured in LOBSFM medium.
- the gated area in (C) and (D) represent cells analyzed for fluorescence.
- Fig. 7 illustrates the number of desmin-positive cells before (pale gray) and after (dark grey) fusion generated after a 25-day culture of H49 cells in STD medium (A) or LOBSFM (B) and of BB13 cells in STD medium (C) or LOBSFM (D).
- Fig. 8 illustrates the doubling time (in days) of BB13 cells cultured in standard (0) or LOBSFM (D) medium in function of initial cellular concentration.
- Fig. 9 compares the expansion of cells in function of days in culture of BB13 cells in standard (0), fresh LOBSFM ( ⁇ ), or frozen/thawed LOBSFM ( ⁇ ) medium.
- Fig. 10 illustrates the total colonies formed per 1 000 of FACS sorted mouse myogenic progenitor cells (gated for nucleated, live cells using Hoechst "1" , and Pl “ , and stained with CD31 " , CD45 " , seal " , and alpha7 + antibodies were used) in (A) basal medium, (B) standard medium and (C) LOBSFM medium.
- A) basal medium (B) standard medium and (C) LOBSFM medium.
- DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT Broadly, the present application relates to a culture medium that enables the in vitro expansion of cells of the myogenic lineage (such as muscular stem cells, myoblasts and myoblast-derived cells) that is free of serum.
- the main advantages of this serum-free culture medium is its safety, the elimination of growth inhibitors contained in serum, a more consistent lot to lot medium composition, and easier approbation by regulating authorities for its use in clinical trials (Freshney 2005).
- the proposed culture medium allows cells to proliferate rapidly and to high concentration without an adaptation period. That period is often necessary to slowly adapt the cells by reducing progressively serum concentration. It also permits the rapid proliferation of cells to a high concentration if the cells are seeded at a low concentration (such as 10 000 cells/ml). Further, the serum-free medium does not stimulate the differentiation and fusion of myoblasts into myotubes.
- the serum-free medium allows cultured myoblasts to maintain their capacity to form myotubes in vitro when transferred into a differentiating medium. Consequently, it is contemplated that the cells cultured in the medium retain their ability to fuse to muscle fibers in vivo.
- the culture medium provided herein is for a cell of the myogenic lineage.
- the term "cell of the myogenic lineage” refers to a cell capable of expressing genes and proteins specific to myoblasts or to a cell having a myoblastic phenotype.
- Myoblast-specific genes and proteins include, but are not limited to, MyoD, Myf5, MRF4, myogenin, Pax3, Pax7, desmin, creatine phosphokinase, muscle-specific myosin, Mind bomb 2, ⁇ -actin, troponin-l, actinin, MyHC, zeugmatin, titin, nebulin and MyBP-C.
- the myoblastic phenotype encompasses the ability of a myoblast to fuse to generate a muscle cell and form myotubes or to de-differentiate into a satellite cell.
- Muscular stem cells are known to differentiate into myoblasts.
- Myoblast-derived cells include, but are not limited to, muscle cells and satellite cells.
- Muscle cells or muscle fibers have an elongated, cylindrical shape and are multinucleated. The nuclei of these muscles are located in the peripheral aspect of the cell (Totsuka 1987), just under the plasma membrane, which vacates the central part of the muscle fiber for myofibrils.
- the muscle cells are also referred to as a myocytes (also known as myocardial cells).
- Each myocardial cell contain myofibrils, which are long chains of sarcomeres, the contractile units of the cell.
- Myocytes show similar pattern to skeletal muscle cells, unlike multinucleated skeletal cells, myocytes contain only one nucleus.
- Satellite cells are small mononuclear progenitor cells with very little cytoplasm and can be found in the mature muscle. They are usually located between the basal lamina and sarcolemma of individual muscle fibers. Satellite cells are able to differentiate and fuse to augment existing muscle fibers and to form new fibers. In undamaged muscle, the majority of satellite cells are quiescent. In response to a mechanical strain, satellite cells become activated; they initially proliferate as skeletal myoblasts before undergoing myogenic differentiation. Satellite cells express a number of distinctive genetic markers such as Pax7 and Pax3. Activated satellite cells also express myogenic transcription factors, such as Myf5 and MyoD. Differentiated satellite cells express muscle-specific filament proteins such as desmin.
- the cells that can be cultured in the serum-free medium are preferably those of the myogenic lineage. These cells include, but are not limited to, commercially available cell lines (such as the C 2 C 12 cell line) as well as primary cultures of cells. In the latter, the cells can be obtained from a tissue biopsy (such as a biopsy of a healthy muscle tissue) or can be derived from stem cells (such as those present in blood (such as cord blood), skin, muscles, etc). Cells of the myogenic lineage of any origin (such as mammalian cells, murine cells and human cells) can be successfully cultured in the serum-free medium. The serum-free medium could be used for the culture of adherent cells and nonadherent cells.
- the serum-free culture medium allows the proliferation of the cells of the myogenic lineage at a rate similar to the rate that would be obtained with a standard medium with serum.
- the expression "similar rate of proliferation” refers to a rate of proliferation that is either not statistically different or superior to cells cultured in standard serum-containing medium.
- commercially available serum-free culture media such as the SkGM ® medium from Lonza
- the culture medium proposed herein provides a tangible advantage when compared to the existing media in the art.
- the culture medium contains at least two components (i) a basal medium and (ii) a cytokine.
- the basal medium provides a source of consumable energy for the cells, a source of amino acids, minerals, vitamins, salts, trace elements.
- the basal medium can be either a single medium or a combination of more than one medium.
- Basal medium contemplated for incorporation into the serum-free medium can be, for example, Dulbecco's Modified Eagle's Medium (DMEM), advanced DMEM, Biogro, SkGM ® , Ham's F10, Ham's F12, Iscove's modified Dulbecco's medium, neurobasal medium, RPMI 1640 and/or MCDB120.
- the basal medium is a combination of Ham's F12, RPMI 1640 and MCDB120 media.
- the ratio between these three basal media is approximatively 1 :1 :1.
- the second component of the culture medium is a cytokine.
- cytokines play a crucial role in the activation, growth, proliferation and differentiation of myoblasts.
- the first phase of muscular repair is necrosis of damaged parts and the activation of the inflammatory response (Charge and Rudnicki 2004).
- the latter is characterized by the secretion of cytokines by damaged fibers and the cells of the immune system.
- These cytokines activate quiescent satellite cells who then enter the cellular cycle and proliferate. This activation triggers myogenesis, a series of complex events which involves the differentiation of satellite cells into muscle precursor cells, and the fusion of the later to form muscle fibers.
- the inflammatory response fades and the satellite cells return to their quiescent state (Miller et al. 2000; Muntoni et al. 2002).
- cytokines In order to develop the serum-free culture medium, Applicant has investigated which cytokines could become valuable potential additives to the basal medium. Cytokines are often specific to a cell type, play several important roles in the body, regulate many processes, influence cellular survival, growth and differentiation, etc. In myoblasts, cytokines are also involved in the assembly of the actin cytoskeleton and the mobility of the cells (Kurek et al. 1998; Cooper and Hausman, 2007). Generally, cytokines have the following characteristics:
- the concentration of cytokines needed to induce an effect is very low, (in the ng/ml range) since receptor affinity for its ligand is generally very high and binding often leads to signal amplification.
- Cytokines are part of complex reaction networks, an act in either positive or negative synergy with other cytokines. Multiple cytokines also act in sequence to lead to the complete response (Fitzgerald et al. 2001 ; Hancock, 2005; Lewin, et al. 2007).
- cytokinines New cytokines are discovered each year, but until now, 80 are known and their mass varies between 10 and 70 kDa (Hancock 2005). Cytokines were originally described as soluble polypeptides used as communication agents between lymphoid cells. However, cytokine definition is now broader and designate any protein which acts on proliferation or differentiation, whereas "growth factor"
- GF is used specifically to define cytokines with a positive effect on cellular division.
- GF Several GF are secreted by macrophages during the immune response and by skeletal muscle cells in an autocrine manner. Generally, they act as progression factors of the cell cycle that prevent the formation of myotubes, but would also contribute to the maturation of muscle fibers and the migration of myoblasts (Kinoshita et al. 1995; Allen et al. 2003; Lafreniere et al. 2004).
- FGFs fibroblast growth factors
- EGF epidermal growth factors
- TGF ⁇ insulin-like growth factor
- TGFs transforming growth factors
- BMPs bone morphogenic factors
- HGF hepatocyte growth Factor
- LIF leukemia inhibitory factor
- PDGFs platelet- derived growth factor
- VEGF vascular-endothelial growth factor
- M-CSF macrophage colony-stimulating factor
- NGF nerve growth factor
- lnterleukins are the principal group of hematopoietic cytokines. They allow communication between cells of the immune and inflammatory systems and control the growth and the differentiation of several cell types. The macrophages and the monocytes produce several types of interleukins that could play an important role in muscle skeletal cell proliferation. To our knowledge, very few project studied the effects of interleukins on muscular cell proliferation, which makes their investigation interesting.
- LIF leukemia inhibitory factor
- IL-1 is a cytokine which modulates cellular proliferation by the induction and the inhibition of others cytokines and is a precursor of the inflammatory response (Wang et al. 2005).
- IL-1 ⁇ induces the production of IL-6, arachidonic acid, human growth hormone, nitric oxide and certain inflammatory proteins, such as collagenase and elastase, in myoblasts (Mizel, 1989; Fitzgerald et al. 2001 ; Adams et al. 2002; Chevrel et al. 2005).
- IGF-1 would prevent IGF-1 from promoting protein synthesis, down-regulating myogenin by the means of ceramide production, a secondary messenger (Broussard et al. 2004; Strle et al. 2004).
- cytokines In the serum-free medium, many cytokines (such as those listed above) can be added. They can be in a purified form, derived from humans or animals or they can be obtained through recombinant technology. Many cytokines are readily available commercially. In one embodiment, the cytokines can either be one or more growth factors (such as FGF, EGF, BMP, TGF ⁇ or IGF), and/or one or more interleukins (such as IL-1 to IL-33), and/or one or more hematopoietic cytokines (such as ILs, EPO or M-CSF). The concentration of the growth factors varies but it is usually in a range between about 1 to 100 ng/ml.
- growth factors such as FGF, EGF, BMP, TGF ⁇ or IGF
- interleukins such as IL-1 to IL-33
- hematopoietic cytokines such as ILs, EPO or M-CSF.
- the concentration of interleukin also varies, but it is usually in a range between about 0.1 to 100 ng/ml.
- the culture medium could also comprise a supplement.
- This supplement will allow the proliferation of the cells of the myogenic lineage, limit cell death or senescence and/or enable the cells to retain their ability to differentiate into muscle cells.
- Such supplements can include, but are not limited to (i) a combination of insulin, transferrin and selenite (also known as ITS), (ii) a commercially available B27 supplement (content listed in Table 5, as well as in Brewer et al. 1993), (iii) a combination of dexamethasone, insulin, EGF, fetuin and albumin (also known as Ham's modified additive supplement described in Ham et al.
- ITS 100X solution ranges between 0.005% and 2.5% (v/v).
- Antimicrobial compounds can also be added to the medium to prevent microbial growth during culture, inasmuch as they do not alter cell proliferation, cell death and/or ability to fuse or differentiate.
- Lipids can be useful in the culture of cells and can be added to the serum-free medium.
- useful lipids includes arachidonic acid, cholesterol, DL- ⁇ - tocopherol acetate, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitoleic acid, palmitic acid and stearic acid.
- the concentration of lipids in the culture medium is usually between 0.05% and 5% (v/v).
- Lipids added in the serum-free medium should allow the proliferation of the cells of the myogenic lineage, limit cell death or senescence and enable the cells to retain their ability to differentiate into muscle cells.
- Surfactants can also be added in the serum-free medium, as long as they allow the proliferation of the cells of the myogenic lineage, limit cell death or senescence and enable the cells to retain their ability to differentiate into muscle cells.
- Several surfactants can be used, for example pluronic F-68 ® and Tween ® (such as Tween 80 ® ).
- the present application also relates to a method of culturing a cell of the myogenic lineage.
- this method comprises the step of contacting the cell with the culture medium described herein. Any cell of the myogenic lineage (such as those described herein) can be used in this method.
- the method contemplates the culture of cells on a surface (such as a culture appropriate container or a bead) and the culture of non-attached cells (such as cell lines that form free-floating aggregates in culture).
- the method can be used for short-term culture period (such as about an hour or more than an hour or about a day or more than one day), mid-term culture period (such as about a week or more than a week) or long-term culture period (such as about a month or more than a month).
- short-term culture period such as about an hour or more than an hour or about a day or more than one day
- mid-term culture period such as about a week or more than a week
- long-term culture period such as about a month or more than a month.
- the culture medium enables the proliferation of cells at a rate similar of those cultured in a serum-containing medium. Consequently, the method provided herewith does not alter the proliferating rate of cells when compared to traditional methods using serum.
- the method also has the advantage of limiting cell differentiation in culture while retaining the cell's ability to differentiate when they are placed in a differentiating culture medium or in vivo.
- Another advantage of the culture method presented herewith is that it can be used in the scaling up of large volumes of culture (for example, between 1 to 100 liters).
- the culture medium described herein is free of serum, it can be safely use for the ex vivo expansion of cells that will be implanted or grafted in a patient in need thereof.
- the treatment of muscle deficiencies using ex vivo cultured cells is already known in the art.
- the culture medium described herewith enables the in vitro proliferation of cells of the myogenic lineage while retaining the cultured cell's ability to differentiate (e.g. fuse)
- the present invention provides a new alternative for providing cells for therapy of a muscular deficiency. It is known in the art that the success of such cellular therapy is linked to the number of cells that can be transferred to the patient.
- the culture medium presented herewith does not contain serum (a risk factor for a potential microbial/prion infection) and enables the proliferation of cells in vitro, it is contemplated that it could be successfully used in cellular therapy.
- the present application also relates to the treatment or the alleviation of symptoms of a muscular deficiency in a subject in need thereof.
- the method comprises contacting a cell of the myogenic lineage with the culture medium described herein or culturing a cell of the myogenic lineage according the method described herein.
- the cell is then implanted in a subject in need thereof to treat or alleviate the symptoms associated to a muscular deficiency.
- muscle deficiency refer to a significant reduction in muscle mass in a subject, modifying abilities to maintain posture, movement and ultimately vital functions.
- Muscular deficiency are, for example, any muscular dystrophy (such as Duchenne, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophy), myocardial infarction and urethral sphincter insufficiency.
- the present application also contemplates the use of the serum-free culture medium and cells cultured therein for the treatment or the alleviation of symptoms of a muscular deficiency or dysfunction.
- Myoblasts used in the following examples were derived from three digested human muscular biopsies, BB13, H49 and H51.
- BB13 cells were separated from fibroblasts following the protocol described in Belles-lies et al., 1993, and were therefore at least 95% desmin positive (DakoCytomation clone DE-R-11 , code M0724) and 95% NKH1 (Beckman-Coulter).
- H49 and H51 cells were not purified and contained >50% desmin positive-cells.
- the cells were initially cultured in MCDB120 basal medium (Hyclone SH3A11704.01), complemented with 15% fetal bovine serum (FBS, Hy-Clone SH30396.03, lot
- This medium was also used as a positive control, standard (STD) medium.
- STD standard
- the serum-free medium (also referred to as LOBSFM or LOB-SFM) is composed of a mixture of three basal media.
- the three basal media are Ham F12 (Invitrogen 11765-054), RPMI1640 (Invitrogen 21870-076) and MCDB120 (Hyclone SH3A1704.01 , lot # AQE23666) combined in a 1 :1 :1 ratio.
- the compositions of those three basal media are described in Table 4 and Table 5. This mixture is supplemented with six growth factors/cytokines and seven additives (Table 3), Ham's growth supplement cocktail (Table 1) and its modified version (Table 2).
- the commercially available medium from Lonza, (SkGM ® , Lonza CC-3160) is composed of a basal medium (SkGM ® ) and an additive mixture (BulletKitTM) similar in composition to the Ham's supplement (Table 1): insulin (CC-4025N), rhEGF (CC-4017N), BSA (CC-4160N), fetuin (CC-4140N), GA-1000 (CC- 4081 N) and dexamethasone (CC-4150N).
- Table 4 Amino acid content of Ham F12, RPMI 1640 and MCDB120 media
- Table 5 Vitamins, salts, trace elements, lipids and other additives contained in Ham F12, RPMI 1640 and MCDB120
- Proliferation assays and designs of experiments (DOE). A frozen aliquot of 1-3 x 10 6 myoblasts was thawed and diluted to 2 x 10 5 cells/ml in STD medium in a 75 cm 2 tissue culture T-flask and incubated at 37°C in a humidified, 5% CO 2 atmosphere. After approximately five days, the culture reached 80% confluence, at which point the cells were trypsinized, rinsed and centrifuged three times with phosphate buffer saline (PBS), and inoculated in cell culture multiwell plates (either 6 or 24 wells) at 10 000 cells/ml in the different culture media. No adaptation of cells for serum-free conditions was made before the 0 experiments. Media change was performed every two to three days and cells were counted using a hemacytometer.
- PBS phosphate buffer saline
- the 0 markers used in this study were desmin (DakoCytomation clone DE-R-11 , code M0724), NKH-1 (NKHI-i-RDI/NCAM/CD ⁇ ; Beckman Coulter 6603067) and myosin heavy chain (MHC; MF20 (Iowa Hybridoma Bank)).
- Desmin is a highly specific marker for activated satellite cells and myogenic precursors.
- the anti- desmin antibody stains the intermediate filaments of the cytoskeleton (Freshney 2005).
- NCAM neural cell adhesion molecule
- Culture medium was removed from the culture well when 80%- 90% confluence was reached and it was replaced by a differentiation medium.
- the differentiation medium was composed of RPMI1640/F12/MB1 completed only with ITS (10 ⁇ g/ml insulin, 5.5 ⁇ g/ml transferring, 6.7 ng/ml sodium selenite). Under these conditions, normal myoblasts usually differentiate and fuse to form myotubes within three to four days.
- RT-PCR Reverse-Transcriptase Polymerase-Chain-Reaction
- BB13 cells were used for myoblast expression profiling, since they are a 95-100% pure myoblast population.
- a monocyte/macrophage cell line (ATCC CRL-9855) was also used to study macrophage expression. The ligands of myoblast receptors were also surveyed. Primer for each of these genes were found in the scientific literature and synthesized.
- RNA isolation was done according to the manufacturer instructions (GIBCO). Briefly, 1 E6 cells were mixed with 1 ml of Trizol ® and incubate at room temperature for 5 minutes. Then, 200 ⁇ l/mlTrizol ® of chloroform was added and mixed vigorously for 15 seconds and incubated 3 minutes at room temperature. The mixture was centrifuged for 15 minutes at 12 000g. The aqueous phase containing RNA was recuperated and 500 ⁇ l/ml of TrizolTM of isopropanol for 15 seconds was added at room temperature to allow the precipitation of RNA.
- RNA samples were solubilized in distilled H 2 O ( ⁇ 40 ⁇ l). Total RNA was quantified and assayed for purity with a spectrophotometer (Beckman Coulter DU 650), where a minimum ratio , 6 was considered valuable (samples were diluted 1/200 in TRIS-EDTA).
- RNA (1 ⁇ g) and RNAse free water were use to complete volume to 17 ⁇ l.
- the mixture was heated to 65°C for RNA denaturation and cooled on ice.
- 2 ⁇ l of 10X buffer and 1 ⁇ l de RT were added. Thermocycling of the samples at 42 0 C for 60 minutes and at 70°C for 15 minutes to inactivate the enzyme complete the RT phase.
- the mixture for PCR reaction consisted of dNTPs (0,5 ⁇ l 25 mM), Taq polymerase (20U/ml), Taq buffer 10X (5 ⁇ l), cDNA (2 ⁇ l), forward+reverse primers (2 ⁇ l each) and deonized, RNAse free water (complete to 50 ⁇ l).
- the cycling conditions were as follow: 1 cycle at 94 0 C for 2 minutes; 35 cycles at 94°C for 30 seconds, annealing temperature for 30 seconds and 72°C for 45 seconds; 1 cycle at 72°C for 10 minutes; 1 cycle at 4°C for an indefinite period.
- the amplicons were run on agarose gels to evaluate their concentration and their approximate molecular weight.
- the capacity of seven different culture media to support myoblast expansion was compared with second passage (P2) H49 cells.
- the cells were cultured as described in Example I and were inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500 ⁇ L/well).
- Cells were cultured in either i) STD medium, or ii) a first generation serum-free medium developed in our lab (MBa, composition described in Table 7) without any other addittives, or additioned with either iii) a macrophage conditioned medium (obtained from the supernatant of a macrophage culture (ATCC CRL-9855) in DMEM supplemented with ITS, 48 hours following a stimulation with LPS), iv) IL-1 ⁇ , v) IL-1 ⁇ , vi) calpeptine or vii) with a combination of B27 (refer to Table 8 below), N2 and sonic hedgehog (ShH).
- a macrophage conditioned medium obtained from the supernatant of a macrophage culture (ATCC CRL-9855) in DMEM supplemented with ITS, 48 hours following a stimulation with LPS
- iv) IL-1 ⁇ , v) IL-1 ⁇ vi) calpeptine or vii)
- LOBSFM was compared to a serum-free medium commercially available from Lonza (SkGM ® +BulletKit ® ) and with the standard medium (STD).
- BB13 cells in P 4 were cultured as described in Example I.
- the cells were inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500 ⁇ L/well) and cultured in either standard medium, SkGM ® serum-free medium completed with the BulletKitTM additives, LOBSFM serum-free medium or SkGM ® serum-free medium completed with LOBSFM additives.
- the cell were counted with a hemacytometer at three and five days post-plating. As shown in Fig.
- BB13 cells in P 4 were cultured as described in Example I.
- the cells were trypsinized and inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500 ⁇ L/well) at a concentration of 10 000 cells/ml.
- the results shown in Fig. 3 represent two experiments carried out independently. The monitoring of cellular expansion accounts for the subsequent dilution of the culture, and is therefore expressed in expansion fold.
- BB13 cells first cultured in the STD medium fused efficiently when transferred to the differentiation medium (Fig. 4 G and H).
- BB13 cells first cultured for 25 days in the LOBSFM showed similar, or even higher, ability to form myotubes and fuse (Fig. 7).
- BB13 cells Myoblasts cultured for four weeks in LOBSFM or STD medium exhibited similar proportion of NKH-1 expressing BB13 cells (Fig. 6 A). However, although the expression levels were similar for BB13 cells, it was lower for non-purified H49 cells cultured in LOBSFM (Fig. 6 B).
- the CNTF ciliary neurotrophic factor
- myoblast clones (desmin + ) to form multipotent progenitors, having a self-renewal capacity and being able to form several cellular types, in particular neurons, smooth muscles cells and adipocytes. These cells proliferated during more than 20 passages without expressing the muscle regulatory factor (MRF) and it was possible to differentiate them back to the myogenic lineage afterward (Chen et al. 2005).
- MRF muscle regulatory factor
- IL-1 ⁇ blocked myogenin expression and the synthesis of several other proteins (Broussard et al. 2004).
- TWEAK decreases not only the expression of myogenin and MyoD, but also of the actin filaments (Girgenrath et al. 2006). Consequently, the reduction of a marker expression during a culture, such as observed here for desmin in LOBSFM-cultured myoblasts, is not necessarily indicative of a loss in myogenesis capacity.
- the most important test for testing the functionality of myoblasts is a functional fusion in vitro assay to determine the potential of the cells to fuse together to form myotubes or a functional in vivo fusion assay in DMD patients.
- the added benefit of the in vitro assay is that it can be performed rapidly as a routine assay and is a good indicator of the in vivo situation.
- RNA of P 3 BB13 cells cultured in STD medium for one passage has been isolated with TRIzol ® .
- the intensity of the RT-PCR product staining on an agarose gel has been listed in
- Table 9 List of genes detected by RT-PCR and classified according to the bands on the agarose gel
- P 4 BB13 cells were trypsinized and inoculated in 6-well plasma treated plates (Sarstedt 83.1839, 2 ml/well) at a concentration of either 2 000, 10 000 or 40 000 cells/ml in STD medium or LOBSFM. Cells were counted on the fifth day of culture. As shown in Fig. 8, the minimal initial cell concentration of 10 000 cell/ml allowed the culture to grow at a rate similar to the higher initial cell density No statistical difference in the results obtained with the two culture media (STD and LOBSFM) was observed.
- P 4 BB13 were trypsinised and inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500 ⁇ L/well) at an initial density of 10 000 cells/ml in either fresh STD medium or LOBSFM, or LOBSFM that has been frozen at -20 0 C overnight, and then thawed. As shown in Fig. 9, a previously frozen LOBSFM does not significantly impact its capacity to expand myoblasts.
- IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts. J Immunol 172(12): 7713-20.
- TWEAK via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration.
- Embo J 25(24): 5826-39. Goto, S., K. Miyazaki, et al. (1999). "Serum-free culture conditions for analysis of secretory proteinases during myogenic differentiation of mouse C2C12 myoblasts.” Anal Biochem 272(2): 135-42.
- TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 285(2): C370-6.
- Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle. Am J Physiol Cell Physiol 278(1): C174-81.
- TNF- alpha Tumor necrosis factor-alpha
- IL-1 receptor antagonist attenuates MAP kinase/AP-1 activation and MMP1 expression in UVA-irradiated human fibroblasts induced by culture medium from UVB-irradiated human skin keratinocytes.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
This application relates to a serum-free culture medium that enables the proliferation of cell of the myogenic lineage while maintaining their ability to differentiate into functional muscle cells. Also contemplated herewith are method of culturing cells of the myogenic lineages and uses of the cultured cells for the treatment or the alleviation of symptoms of a muscular deficiencies.
Description
CULTURE MEDIUM FOR MYOBLASTS, PRECURSORS THEREOF AND DERIVATIVES THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
This is application claims priority from US provisional application Serial Number 61/098,964 filed on September 22, 2008 and incorporated herewith by reference in its entirety.
BACKGROUND OF THE INVENTION
Duchenne muscular dystrophy (DMD), with a prevalence of 1 boy out of 3500, is the most widely spread genetic disease (Voisin, 2004). This disease is characterized by the progressive weakening of muscles, resulting in muscular necrosis and fibrosis (Emery, 2003). An essential protein for muscle fibers stability, dystrophin, is missing or defective in muscle fibers of DMD patients. Dystrophin is a 427-kDa protein which connects the actin cytoskeleton to the cellular membrane (Bogdanovich et al. 2004). The function of this protein is to maintain the stability of the cellular membrane in order to support the stresses induced during muscular contractions (Carpenter et al. 1990). The absence of dystrophin increases the vulnerability of muscle fibers during their contraction. Consequently, constant muscular repair will be necessary, which will result in the premature senescence of myoblasts.
Cellular therapy, a therapy under development to counter DMD, has shown significant therapeutic effect in several studies in mice (Chen, Li et al. 1992) and humans (Gussoni et al. 1992; Huard et al. 1992; Huard et al. 1994; Skuk et al. 2006; Skuk et al. 2007). This curative approach is regarded as a promising treatment (Skuk and Tremblay, 2000). Presently, cellular therapy consists in injecting human myoblasts in the muscles of the DMD patients. The healthy myoblasts fuse to muscle fibers of the patients and partially restore the expression of dystrophin. This expression increases the strength of the treated muscle and restores at least partially their functionality, hence improving significantly the patient's quality of life. Nevertheless, some difficulties remain to be surmounted, of which the immunizing response against the injected
myoblasts, the absence of fusion of myoblasts with undamaged fibers as well as the poor migration of the myoblasts in the muscle tissue. Moreover, the culture medium presently used for myoblast expansion contains blood serum and the production processes presently used are not adequate for the production of the large number of myoblasts that would be required to treat the whole muscle mass of a patient. Constant and rapid progresses are made on these fronts, through better understanding of myoblast and myogenic cell biology, transplantation and migration, the development of protocols to alleviate immuno-rejection, and the identification of alternative cell sources, e.g. pluripotent stem cells (Skuk et al. 2002). Cellular therapy therefore seems to be on the verge of being the very first accepted therapy against DMD.
In addition to the treatment of DMD, myoblast injections are also used for the treatment of myocardial infarction and for urethral sphincter insufficiency. Indeed, the grafts of myoblasts significantly improve the contractility as well as the viability of cardiac tissues and allows 41 % restoration of the normal sphincter contractility (Yiou et al. 2004; Kahn, 2006).
The nutritional needs of in vitro cultured cells comprise a vast range of molecules, of which several are found in a basal medium, which contains the essential components necessary to the cellular metabolism and osmotic balance maintenance: salts, amino-acids, vitamins, sugars, lipids, trace elements, antioxidants and pH buffer (Ham and McKeehan 1979; Butler, 1991 ; Mather and Barnes 1998; Davis, 2002; Naomoto et al. 2005). The basal medium must be selected considering its compatibility with the type of cells to be cultured, as well as its performance with regards to predetermined responses of interest. The role of the basal medium can therefore either be to support proliferation, differentiation or quiescence of a given cell population (Zimmerman et al. 2000). Basal media known to support myoblast expansion are DMEM, F12, RPMI1640 (Goto et al. 1999) and MCDB120 (Ham et al. 1988).
The medium generally used to culture myoblasts in vitro (standard medium, STD) is MCDB120 supplemented with 15% fetal bovine serum (FBS), 10 ng/ml
basic fibroblast growth factor (bFGF), 0.39 μg/ml dexamethasone and 0.5 mg/ml bovine serum albumin (BSA). Serum is an additive which allows the nonspecific proliferation of a vast range of cell types. It is prepared from plasma, the liquid fraction of blood, from which clotting factors were removed. The principal sources of sera for cell culture are bovine fetal blood (FBS), calf (CS), horse (HS) or human. FBS is the most widely used. Its functions are multiple: adhesion of the cells to a solid surface (via adhesion molecules such as fetuin, fibronectin, vitronectin), growth stimulation (growth factors, GF; cytokines; hormones), protection (antioxidants, antitoxins, proteins), buffer and nutrition. However, serum composition is not completely resolved since it is a very complex fluid, containing at least 3 000 different proteins (Omenn, 2005). Another point to consider is the quickly rising cost of serum, due to an increasing demand (500-600$/L) (Davis, 2002). Moreover, serum requires extensive quality control, it contains proliferation inhibitors, its composition varies from batch to batch, and it hinders the purification of cell culture products. Serum can also be contaminated by viruses, bacteria and prions (Jayme et al. 1988; Freshney, 2000). It is therefore advantageous to replace serum by a mixture of defined components that would not present similar problems. Serum- free media allow a better control of cell proliferation and differentiation and reduce the risk of contamination (Zimmerman et al. 2000). However, serum-free media are much more specific than serum-containing media, often only supporting the growth or differentiation of the cell type for which it has been developed. The corollary of this is therefore that most cell lineage will require the development of their own serum-free medium.
Although serum-free medium formulations for myoblast culture have previously been reported (Ham et al. 1988) or are commercially available (Skeletal muscle cell medium BulletKit™, CC-3160 from Lonza), the extent and rate of myoblast proliferation in these media remains much lower than in serum containing media. To this date, Applicant is not aware of any effective serum-free medium for myoblast expansion.
Consequently, the development of a safer, serum-free culture medium that would efficiently support the expansion of myoblasts and their precursors would
significant and timely contribute to the advent of cellular therapy based on the use of these cells.
SUMMARY OF THE INVENTION
The present invention relates to a culture medium for cells of the myogenic lineage that is free of serum and/or any other undefined supplement. This serum-free culture medium allows the cells to proliferate at a rate that is similar to the one of cells cultured in a serum-containing medium. The present invention also relates to a method for culturing cells in vitro where the serum- free medium is used. The use of the cells cultured in the serum-free media in cellular therapy for muscle-associated conditions is also contemplated.
According to a first aspect, the present invention provides a culture medium for a cell of the myogenic lineage. In an embodiment, the culture medium comprises a basal medium and a cytokine or a combination of cytokines. Preferably, the culture medium is free of serum and allows the proliferation of the cell of the myogenic lineage at a similar rate than another cell of the myogenic lineage cultured in a standard medium containing serum. In an embodiment, the cell of the myogenic lineage is at least one of a muscular stem cell, a myoblast and a myoblast-derived cell. In another embodiment, the muscular stem cell can differentiate into a myoblast. In yet another embodiment, the myoblast-derived cell is at least one of a muscle cell, a satellite cell and a myocyte. In still another embodiment, the cell of the myogenic lineage is derived from a biopsy, is a mammalian cell and/or is a human cell. In an embodiment, the basal medium is at least one of Dulbecco's modified Eagles's medium (DMEM), advanced DMEM, Biogro™, SkGM®, Ham's F10, Ham's F12, Iscove's modified Dulbecco's medium, neurobasal medium, RPMI 1640 and MCDB120 medium. In another embodiment, the basal medium is a combination of Ham's F12, RPMI 1640 and MCDB120 and, in a further embodiment, the proportion of Ham's F12, RPMI 1640 and MCDB120 is about 1 :1 :1. In an embodiment, the cytokine is a human cytokine. In still another embodiment, the cytokine is a recombinant cytokine. In yet another embodiment, the cytokine is at least one of a growth factor (GF) and an interleukin. In still another embodiment, the growth
factor is at least one of a fibroblast growth factor (FGF), an epidermal growth factor (EGF) and an insulin-like growth factor (IGF). In yet another embodiment, the concentration of FGF in the culture medium is between about 1 and 20 ng/ml. In an embodiment, the FGF is at least one of FGF-1 , FGF-2, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8 and FGF-9. In still another embodiment, the concentration of EGF in the culture medium is between about 1 and 20 ng/ml. In yet another embodiment, the concentration of IGF in the culture medium is between about 1 and 50 ng/ml. In an embodiment, the IGF is at least one of IGF-1 and IGF-2. In still another embodiment, the concentration of interleukin in the culture medium is between about 0.1 to 20 ng/ml. In an embodiment, the interleukin is at least one of IL-I , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 , IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21 , IL-22, IL- 23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31 , IL-32 and IL-33. In yet another embodiment, the culture medium further comprises a supplement and, in yet another embodiment, the supplement is at least one of: i) a combination of insulin (at a concentration, for example, of 0.5 mg/ml), transferrin (at a concentration, for example, of 5 mg/ml) and selenite (at a concentration, for example, of 0.52 μg/ml) (ITS); ii) B27 medium supplement; iii) a combination of dexamethasone, insulin, EGF, fetuin and albumin; and iv) a combination of dexamethasone, bFGF, albumin and insulin. In still another embodiment, the concentration of ITS in the culture medium is between about 0.5 and 2.5% v/v. In yet another embodiment, the culture medium further comprises a lipid and, in still another embodiment, the lipid is at least one of arachidonic acid, cholesterol, DL-α-tocopherol acetate, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitoleic acid, palmitic acid and stearic acid. In still another embodiment, the concentration of the lipid in the culture medium is between about 0.5 and 2.5% v/v.
In a second aspect, the present invention provides an in vitro method of culturing a cell of the myogenic lineage. The method can comprise contacting the cell of the myogenic lineage with the culture medium described herein thereby culturing said cell. In an embodiment, the cell of the myogenic lineage is at least one of a muscular stem cell, a myoblast and a myoblast-derived cell. In
a further embodiment, the muscular stem cell can differentiate into a myoblast. In yet another embodiment, the myoblast-derived cell is at least one of a muscle cell, a satellite cell and a myocyte. In an embodiment, the method is performed for at least an hour, for at least a day, for at least a week or for at least a month. In an embodiment, the method reduces the lag phase of the cell of the myogenic lineage with respect to the lag phase of a cell of the myogenic lineage cultured in another serum-free media. In another embodiment, the method enables the long term expansion of the cell of the myogenic lineage. In still another embodiment, the initial concentration of the cell of the myogenic lineage in the culture medium is 10 000 cells/mL In yet another embodiment, the method enables the cell of the myogenic lineage to retain its ability to form a myotube.
In a third aspect, the present invention provides a method of treating or alleviating a muscular deficiency in a subject in need thereof. In an embodiment, the method comprises contacting a cell of the myogenic lineage with the culture medium described herein ; and implanting the cell previously obtained in the subject; thereby treating or alleviating the muscular deficiency in the subject. In an embodiment, the method comprises providing a cell of the myogenic lineage cultured by the method described herein and implanting the cultured cell obtained in the subject; thereby treating or alleviating the muscular- associated condition in the subject. In an embodiment, the subject is a human. In another embodiment, the muscular-deficiency is at least one of Duchenne muscular dystrophy, myocardial infarction, urethral sphincter insufficiency.
In a fourth aspect, the present invention provides the use of a cell of the myogenic lineage cultured in the culture medium described herein or prepared by the method described herein for the treatment or the alleviation of symptoms of a muscular deficiency in a subject. In an embodiment, the subject is a human. In another embodiment, the muscular deficiency is associated with at least one of Duchenne muscular dystrophy, myocardial infarction, urethral sphincter insufficiency.
In a fifth aspect, the present invention provides a cell of the myogenic lineage cultured in the culture medium described herein or prepared by the method described herein for the treatment or the alleviation of symptoms of a muscular deficiency in a subject. In an embodiment, the subject is a human. In another embodiment, the muscular deficiency is associated with at least one of Duchenne muscular dystrophy, myocardial infarction, urethral sphincter insufficiency.
BRIEF DESCRIPTION OF THE DRAWINGS
Having thus generally described the nature of the invention, reference will now be made to the accompanying drawings, showing by way of illustration, a preferred embodiment thereof, and in which:
Fig. 1 compares the expansion of human myoblasts cultured in various media (0, standard (STD) medium; D, first generation serum-free medium (MBa); Δ, MBa supplemented with macrophage conditioned medium (MCM); x, MBa supplemented with interleukin 1α (IL-1α); *, MBa supplemented with IL1 β; o, MBa supplemented with calpeptine; I , MBa supplemented with B27 supplement, N2 supplement and sonic hedgehog (ShH) during the course of a nine-day culture.
Fig. 2 compares the expansion of human myoblasts cultured in various media (o, optimized serum-free medium (LOBSFM); o, Lonza serum-free medium composed of the basal medium SKBM® supplemented with Bulletkit™ additives; Δ, standard medium; x, SKBM® medium supplemented with the LOBSFM additives for five days.
Fig. 3 compares the long-term expansion of BB13 cells in various media (0, standard medium, duplicates 1 and 2; G, LOBSFM, duplicates 1 and 2) expressed in expansion folds in function of time (days).
Fig. 4 shows micrographs of immunostained cells that proliferated in LOBSFM (A to F) and STD medium (G to I) with cell nucleic represented as dots; desmin represented as elongated structures in panels A-C, E and I, myosin heavy chain
represented as elongated structures in panels D, F, G, H. The cells were cultured either for one week (D and G), two weeks (A), four weeks (B, E1 H) or six weeks (C, F, I). Cells in boxes D to H were fixed and immunostained after a three-day incubation in the differentiation medium.
Fig. 5 illustrates the proportion of desmin-expressing cells from independent experiments for (A) BB13 cells in STD medium(O) or LOBSFM (D); and (B) H49 (o) or H51 (Δ) cells in STD medium (solid line) or LOBSFM (broken line).
Fig. 6 shows flow cytometry results of a four weeks myoblast culture. (A) BB13 cellular counts against intensity for NCAM+ cells cultured in LOBSFM (98,8%) or STD medium (96,9%). (B) H49 cellular counts against intensity for cells cultured in LOBSFM (left curve) or standard medium (right curve) as indicated by the arrows. (C) Side scatter against forward scatter for cells cultured in standard medium. (D) Side scatter against forward scatter for cells cultured in LOBSFM medium. The gated area in (C) and (D) represent cells analyzed for fluorescence.
Fig. 7 illustrates the number of desmin-positive cells before (pale gray) and after (dark grey) fusion generated after a 25-day culture of H49 cells in STD medium (A) or LOBSFM (B) and of BB13 cells in STD medium (C) or LOBSFM (D).
Fig. 8 illustrates the doubling time (in days) of BB13 cells cultured in standard (0) or LOBSFM (D) medium in function of initial cellular concentration.
Fig. 9 compares the expansion of cells in function of days in culture of BB13 cells in standard (0), fresh LOBSFM (□), or frozen/thawed LOBSFM (Δ) medium.
Fig. 10 illustrates the total colonies formed per 1 000 of FACS sorted mouse myogenic progenitor cells (gated for nucleated, live cells using Hoechst"1", and Pl", and stained with CD31", CD45", seal", and alpha7+ antibodies were used) in (A) basal medium, (B) standard medium and (C) LOBSFM medium.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT Broadly, the present application relates to a culture medium that enables the in vitro expansion of cells of the myogenic lineage (such as muscular stem cells, myoblasts and myoblast-derived cells) that is free of serum. The main advantages of this serum-free culture medium is its safety, the elimination of growth inhibitors contained in serum, a more consistent lot to lot medium composition, and easier approbation by regulating authorities for its use in clinical trials (Freshney 2005). The proposed culture medium allows cells to proliferate rapidly and to high concentration without an adaptation period. That period is often necessary to slowly adapt the cells by reducing progressively serum concentration. It also permits the rapid proliferation of cells to a high concentration if the cells are seeded at a low concentration (such as 10 000 cells/ml). Further, the serum-free medium does not stimulate the differentiation and fusion of myoblasts into myotubes. However, the serum-free medium allows cultured myoblasts to maintain their capacity to form myotubes in vitro when transferred into a differentiating medium. Consequently, it is contemplated that the cells cultured in the medium retain their ability to fuse to muscle fibers in vivo.
According to one aspect, the culture medium provided herein is for a cell of the myogenic lineage. As used herein, the term "cell of the myogenic lineage" refers to a cell capable of expressing genes and proteins specific to myoblasts or to a cell having a myoblastic phenotype. Myoblast-specific genes and proteins include, but are not limited to, MyoD, Myf5, MRF4, myogenin, Pax3, Pax7, desmin, creatine phosphokinase, muscle-specific myosin, Mind bomb 2, α-actin, troponin-l, actinin, MyHC, zeugmatin, titin, nebulin and MyBP-C. The myoblastic phenotype encompasses the ability of a myoblast to fuse to generate a muscle cell and form myotubes or to de-differentiate into a satellite cell.
Cells of the myogenic lineage include muscular stem cell, myoblast and myoblast-derived cells. Muscular stem cells are known to differentiate into myoblasts. Myoblast-derived cells include, but are not limited to, muscle cells and satellite cells. Muscle cells or muscle fibers have an elongated, cylindrical shape and are multinucleated. The nuclei of these muscles are located in the
peripheral aspect of the cell (Totsuka 1987), just under the plasma membrane, which vacates the central part of the muscle fiber for myofibrils. In the heart, the muscle cells are also referred to as a myocytes (also known as myocardial cells). Each myocardial cell contain myofibrils, which are long chains of sarcomeres, the contractile units of the cell. Myocytes show similar pattern to skeletal muscle cells, unlike multinucleated skeletal cells, myocytes contain only one nucleus. Satellite cells are small mononuclear progenitor cells with very little cytoplasm and can be found in the mature muscle. They are usually located between the basal lamina and sarcolemma of individual muscle fibers. Satellite cells are able to differentiate and fuse to augment existing muscle fibers and to form new fibers. In undamaged muscle, the majority of satellite cells are quiescent. In response to a mechanical strain, satellite cells become activated; they initially proliferate as skeletal myoblasts before undergoing myogenic differentiation. Satellite cells express a number of distinctive genetic markers such as Pax7 and Pax3. Activated satellite cells also express myogenic transcription factors, such as Myf5 and MyoD. Differentiated satellite cells express muscle-specific filament proteins such as desmin.
The cells that can be cultured in the serum-free medium are preferably those of the myogenic lineage. These cells include, but are not limited to, commercially available cell lines (such as the C2C12 cell line) as well as primary cultures of cells. In the latter, the cells can be obtained from a tissue biopsy (such as a biopsy of a healthy muscle tissue) or can be derived from stem cells (such as those present in blood (such as cord blood), skin, muscles, etc). Cells of the myogenic lineage of any origin (such as mammalian cells, murine cells and human cells) can be successfully cultured in the serum-free medium. The serum-free medium could be used for the culture of adherent cells and nonadherent cells.
As herein described, the serum-free culture medium allows the proliferation of the cells of the myogenic lineage at a rate similar to the rate that would be obtained with a standard medium with serum. As used herein, the expression "similar rate of proliferation" refers to a rate of proliferation that is either not statistically different or superior to cells cultured in standard serum-containing
medium. As shown below in the Examples, commercially available serum-free culture media (such as the SkGM® medium from Lonza) for cells of the myogenic lineage do not enable the growth and proliferation of the cells at a rate similar to the standard medium with serum. The culture medium proposed herein provides a tangible advantage when compared to the existing media in the art.
The culture medium contains at least two components (i) a basal medium and (ii) a cytokine. The basal medium provides a source of consumable energy for the cells, a source of amino acids, minerals, vitamins, salts, trace elements. The basal medium can be either a single medium or a combination of more than one medium. Basal medium contemplated for incorporation into the serum-free medium can be, for example, Dulbecco's Modified Eagle's Medium (DMEM), advanced DMEM, Biogro, SkGM®, Ham's F10, Ham's F12, Iscove's modified Dulbecco's medium, neurobasal medium, RPMI 1640 and/or MCDB120. In a preferred embodiment, the basal medium is a combination of Ham's F12, RPMI 1640 and MCDB120 media. In another embodiment, the ratio between these three basal media is approximatively 1 :1 :1.
The second component of the culture medium is a cytokine. As it is known in the art, cytokines play a crucial role in the activation, growth, proliferation and differentiation of myoblasts. For example, when the muscle is injured, the first phase of muscular repair is necrosis of damaged parts and the activation of the inflammatory response (Charge and Rudnicki 2004). The latter is characterized by the secretion of cytokines by damaged fibers and the cells of the immune system. These cytokines activate quiescent satellite cells who then enter the cellular cycle and proliferate. This activation triggers myogenesis, a series of complex events which involves the differentiation of satellite cells into muscle precursor cells, and the fusion of the later to form muscle fibers. Finally, once the muscle repaired, the inflammatory response fades and the satellite cells return to their quiescent state (Miller et al. 2000; Muntoni et al. 2002).
In order to develop the serum-free culture medium, Applicant has investigated which cytokines could become valuable potential additives to the basal medium.
Cytokines are often specific to a cell type, play several important roles in the body, regulate many processes, influence cellular survival, growth and differentiation, etc. In myoblasts, cytokines are also involved in the assembly of the actin cytoskeleton and the mobility of the cells (Kurek et al. 1998; Cooper and Hausman, 2007). Generally, cytokines have the following characteristics:
• They have different effects on different cell or tissue, due to the difference in expression of their respective receptors on any given cell type (Schlessinger and Ullrich, 1992; Fitzgerald et al. 2001).
• Different cytokines can induce similar reactions since several receptors share similar intracellular signaling pathways. These cytokines are thus known as redundant.
• The concentration of cytokines needed to induce an effect is very low, (in the ng/ml range) since receptor affinity for its ligand is generally very high and binding often leads to signal amplification.
• Cytokines are part of complex reaction networks, an act in either positive or negative synergy with other cytokines. Multiple cytokines also act in sequence to lead to the complete response (Fitzgerald et al. 2001 ; Hancock, 2005; Lewin, et al. 2007).
New cytokines are discovered each year, but until now, 80 are known and their mass varies between 10 and 70 kDa (Hancock 2005). Cytokines were originally described as soluble polypeptides used as communication agents between lymphoid cells. However, cytokine definition is now broader and designate any protein which acts on proliferation or differentiation, whereas "growth factor"
(GF) is used specifically to define cytokines with a positive effect on cellular division.
Several GF are secreted by macrophages during the immune response and by skeletal muscle cells in an autocrine manner. Generally, they act as progression factors of the cell cycle that prevent the formation of myotubes, but would also
contribute to the maturation of muscle fibers and the migration of myoblasts (Kinoshita et al. 1995; Allen et al. 2003; Lafreniere et al. 2004).
Until now, around 50 GF have been identified and several affect muscle cells, such as family members of the fibroblast growth factors (FGFs), epidermal growth factors (EGF, HB-EGF, TGFα), insulin-like growth factor (IGFs), transforming growth factors (TGFs), bone morphogenic factors (BMPs), hepatocyte growth Factor (HGF), leukemia inhibitory factor (LIF), platelet- derived growth factor (PDGFs), vascular-endothelial growth factor (VEGF), macrophage colony-stimulating factor (M-CSF) and nerve growth factor (NGF) (Floss et al. 1997; Fitzgerald et al. 2001). Some GF receptors are expressed in several types of cells (FGF, EGF, IGF-1) whereas others, such colony- stimulating factor (CSF) and the NGF, are more specific (Schlessinger and Ullrich, 1992).
lnterleukins are the principal group of hematopoietic cytokines. They allow communication between cells of the immune and inflammatory systems and control the growth and the differentiation of several cell types. The macrophages and the monocytes produce several types of interleukins that could play an important role in muscle skeletal cell proliferation. To our knowledge, very few project studied the effects of interleukins on muscular cell proliferation, which makes their investigation interesting.
The most studied hematopoietic cytokines are the leukemia inhibitory factor (LIF) of the IL-6 family, IL-1 (α and β) and TNFα. LIF specifically stimulates the proliferation and the survival of myoblasts, without supporting those of fibroblasts. TNFα pushes satellite cells to enter and to remain in the cell cycle, induced IL-6 production, stimulates angiogenesis, increases migration and acts as mitogen for rat myoblasts (Austin et al. 1992; White et al. 2001 ; Ferrara et al. 2003; Li, 2003; Torrente et al. 2003; Langen et al. 2004; Chevrel et al. 2005). Finally, IL-1 is a cytokine which modulates cellular proliferation by the induction and the inhibition of others cytokines and is a precursor of the inflammatory response (Wang et al. 2005). For example, IL-1 β induces the production of IL-6, arachidonic acid, human growth hormone, nitric oxide and certain inflammatory
proteins, such as collagenase and elastase, in myoblasts (Mizel, 1989; Fitzgerald et al. 2001 ; Adams et al. 2002; Chevrel et al. 2005). Moreover, it would prevent IGF-1 from promoting protein synthesis, down-regulating myogenin by the means of ceramide production, a secondary messenger (Broussard et al. 2004; Strle et al. 2004).
In the serum-free medium, many cytokines (such as those listed above) can be added. They can be in a purified form, derived from humans or animals or they can be obtained through recombinant technology. Many cytokines are readily available commercially. In one embodiment, the cytokines can either be one or more growth factors (such as FGF, EGF, BMP, TGFβ or IGF), and/or one or more interleukins (such as IL-1 to IL-33), and/or one or more hematopoietic cytokines (such as ILs, EPO or M-CSF). The concentration of the growth factors varies but it is usually in a range between about 1 to 100 ng/ml. The concentration of interleukin also varies, but it is usually in a range between about 0.1 to 100 ng/ml. When selecting the cytokine to be added in the serum- free medium, one should take care in selecting a cytokine or a combination of cytokines that it will allow the proliferation of the cells of the myogenic lineage, limit cell death or senescence and enable the cells to retain their ability to differentiate into muscle cells.
The culture medium could also comprise a supplement. This supplement will allow the proliferation of the cells of the myogenic lineage, limit cell death or senescence and/or enable the cells to retain their ability to differentiate into muscle cells. Such supplements can include, but are not limited to (i) a combination of insulin, transferrin and selenite (also known as ITS), (ii) a commercially available B27 supplement (content listed in Table 5, as well as in Brewer et al. 1993), (iii) a combination of dexamethasone, insulin, EGF, fetuin and albumin (also known as Ham's modified additive supplement described in Ham et al. 1988, as well as in Table 1) and/or (iv) a combination of dexamethasone, insulin, bFGF and albumin (Table 2). The concentration of these supplement will vary depending on their intended use. Usually, the concentration of a ITS 100X solution ranges between 0.005% and 2.5% (v/v).
Antimicrobial compounds (such as antibiotics) can also be added to the medium to prevent microbial growth during culture, inasmuch as they do not alter cell proliferation, cell death and/or ability to fuse or differentiate.
Lipids can be useful in the culture of cells and can be added to the serum-free medium. Examples of useful lipids includes arachidonic acid, cholesterol, DL-α- tocopherol acetate, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitoleic acid, palmitic acid and stearic acid. The concentration of lipids in the culture medium is usually between 0.05% and 5% (v/v). Lipids added in the serum-free medium should allow the proliferation of the cells of the myogenic lineage, limit cell death or senescence and enable the cells to retain their ability to differentiate into muscle cells.
Surfactants can also be added in the serum-free medium, as long as they allow the proliferation of the cells of the myogenic lineage, limit cell death or senescence and enable the cells to retain their ability to differentiate into muscle cells. Several surfactants can be used, for example pluronic F-68® and Tween® (such as Tween 80®).
The present application also relates to a method of culturing a cell of the myogenic lineage. In an embodiment, this method comprises the step of contacting the cell with the culture medium described herein. Any cell of the myogenic lineage (such as those described herein) can be used in this method. The method contemplates the culture of cells on a surface (such as a culture appropriate container or a bead) and the culture of non-attached cells (such as cell lines that form free-floating aggregates in culture). The method can be used for short-term culture period (such as about an hour or more than an hour or about a day or more than one day), mid-term culture period (such as about a week or more than a week) or long-term culture period (such as about a month or more than a month). As described above, the culture medium enables the proliferation of cells at a rate similar of those cultured in a serum-containing medium. Consequently, the method provided herewith does not alter the proliferating rate of cells when compared to traditional methods using serum. The method also has the advantage of limiting cell differentiation in culture while
retaining the cell's ability to differentiate when they are placed in a differentiating culture medium or in vivo.
Another advantage of the culture method presented herewith is that it can be used in the scaling up of large volumes of culture (for example, between 1 to 100 liters).
Because the culture medium described herein is free of serum, it can be safely use for the ex vivo expansion of cells that will be implanted or grafted in a patient in need thereof. As described above, the treatment of muscle deficiencies using ex vivo cultured cells is already known in the art. However, because the culture medium described herewith enables the in vitro proliferation of cells of the myogenic lineage while retaining the cultured cell's ability to differentiate (e.g. fuse), the present invention provides a new alternative for providing cells for therapy of a muscular deficiency. It is known in the art that the success of such cellular therapy is linked to the number of cells that can be transferred to the patient. Because the culture medium presented herewith (as well as its corresponding method of using the culture medium) does not contain serum (a risk factor for a potential microbial/prion infection) and enables the proliferation of cells in vitro, it is contemplated that it could be successfully used in cellular therapy.
As such, the present application also relates to the treatment or the alleviation of symptoms of a muscular deficiency in a subject in need thereof. The method comprises contacting a cell of the myogenic lineage with the culture medium described herein or culturing a cell of the myogenic lineage according the method described herein. The cell is then implanted in a subject in need thereof to treat or alleviate the symptoms associated to a muscular deficiency. As used herein, the term "muscular deficiency" refer to a significant reduction in muscle mass in a subject, modifying abilities to maintain posture, movement and ultimately vital functions. Muscular deficiency are, for example, any muscular dystrophy (such as Duchenne, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophy), myocardial infarction and urethral sphincter insufficiency.
The present application also contemplates the use of the serum-free culture medium and cells cultured therein for the treatment or the alleviation of symptoms of a muscular deficiency or dysfunction.
The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
EXAMPLE I - METHODOLOGY USED
Cell culture and media. Myoblasts used in the following examples were derived from three digested human muscular biopsies, BB13, H49 and H51. BB13 cells were separated from fibroblasts following the protocol described in Belles-lies et al., 1993, and were therefore at least 95% desmin positive (DakoCytomation clone DE-R-11 , code M0724) and 95% NKH1 (Beckman-Coulter). H49 and H51 cells were not purified and contained >50% desmin positive-cells. The cells were initially cultured in MCDB120 basal medium (Hyclone SH3A11704.01), complemented with 15% fetal bovine serum (FBS, Hy-Clone SH30396.03, lot
KPF21343) and the modified Ham's supplement (refer to Table 2 below). This medium was also used as a positive control, standard (STD) medium. This STD medium is the one presently used to support myoblast proliferation for current clinical trials of in vivo muscular treatments.
Table 1 : Culture medium supplement proposed by Ham (Ham et al. 1988)
Table 2 : Modified culture medium supplement used in the standard medium
Table 3 : Cytokines and additives mixture added in LOBSFM
The serum-free medium (also referred to as LOBSFM or LOB-SFM) is composed of a mixture of three basal media. The three basal media are Ham F12 (Invitrogen 11765-054), RPMI1640 (Invitrogen 21870-076) and MCDB120 (Hyclone SH3A1704.01 , lot # AQE23666) combined in a 1 :1 :1 ratio. The compositions of those three basal media are described in Table 4 and Table 5. This mixture is supplemented with six growth factors/cytokines and seven additives (Table 3), Ham's growth supplement cocktail (Table 1) and its modified version (Table 2).
The commercially available medium from Lonza, (SkGM®, Lonza CC-3160) is composed of a basal medium (SkGM®) and an additive mixture (BulletKit™) similar in composition to the Ham's supplement (Table 1): insulin (CC-4025N), rhEGF (CC-4017N), BSA (CC-4160N), fetuin (CC-4140N), GA-1000 (CC- 4081 N) and dexamethasone (CC-4150N).
Table 4: Amino acid content of Ham F12, RPMI 1640 and MCDB120 media
Table 5: Vitamins, salts, trace elements, lipids and other additives contained in Ham F12, RPMI 1640 and MCDB120
Proliferation assays and designs of experiments (DOE). A frozen aliquot of 1-3 x 106 myoblasts was thawed and diluted to 2 x 105 cells/ml in STD medium in a 75 cm2 tissue culture T-flask and incubated at 37°C in a humidified, 5% CO2 atmosphere. After approximately five days, the culture reached 80% confluence, at which point the cells were trypsinized, rinsed and centrifuged three times with phosphate buffer saline (PBS), and inoculated in cell culture multiwell plates (either 6 or 24 wells) at 10 000 cells/ml in the different culture media. No adaptation of cells for serum-free conditions was made before the 0 experiments. Media change was performed every two to three days and cells were counted using a hemacytometer.
lmmunostaining assays. Cells recuperated from an enzymatic digestion of a muscular biopsy form a heterogeneous cellular population, even when myoblast enrichment is performed. An efficient myoblast culture medium will not only 5 allow extensive and rapid proliferation of any cells, but will also specifically favor myoblast proliferation. Consequently, characterization of cell population at different points in time during their expansion is important. To do so, immunostaining was performed, and the degree of expression of myoblast specific markers was assessed either by microscopy or flow cytometry. The 0 markers used in this study were desmin (DakoCytomation clone DE-R-11 , code M0724), NKH-1 (NKHI-i-RDI/NCAM/CDδδ; Beckman Coulter 6603067) and myosin heavy chain (MHC; MF20 (Iowa Hybridoma Bank)). Desmin is a highly specific marker for activated satellite cells and myogenic precursors. The anti- desmin antibody stains the intermediate filaments of the cytoskeleton (Freshney 2005). NCAM (neural cell adhesion molecule) is a glycoprotein found at high
concentration on the plasma membrane of myoblasts and progenitors of muscular skeletal cells (Nomura, Ashihara et al. 2007), but also on neurons and on natural killer cells (NK). NCAM is thus a little less specific than desmine for myoblasts. MHC indicates the formation of myotubes. DAPI (Sigma D8417) was also used to color the nucleus. In order to perform desmin and MHC staining, cells were rinsed and agitated three times with PBS1 incubated 5 minutes each time with fresh PBS; cells were fixed with a solution of ethanol 95%, incubated 10 minutes, and discarded; a solution of PBS supplemented with 10% FBS was added, let to incubate one hour, and discarded; a solution of PBS supplemented with 10% FBS and the antibody (anti-desmin or anti MHC) was added, incubated one hour, and discarded; cells were rinsed and agitated three times in PBS, 5 minutes each time with fresh PBS; a solution of PBS supplemented with 10% FBS and the labeled secondary antibody (with Alexa 488™ or Alexa 546™) was added, incubated one hour, and discarded; cells were rinsed and agitated three times in PBS, 5 minutes each time with fresh PBS; and DAPI was added on the last rinse. At least 500 cells are counted for each condition to allow for proper result accuracy.
Fusion assay. Culture medium was removed from the culture well when 80%- 90% confluence was reached and it was replaced by a differentiation medium. The differentiation medium was composed of RPMI1640/F12/MB1 completed only with ITS (10 μg/ml insulin, 5.5 μg/ml transferring, 6.7 ng/ml sodium selenite). Under these conditions, normal myoblasts usually differentiate and fuse to form myotubes within three to four days.
Reverse-Transcriptase Polymerase-Chain-Reaction (RT-PCR). RT-PCR was used to probe the transcriptome of receptors and autocrine factors expressed by myoblasts, as well as the growth factors expressed by macrophage, since it has been reported that macrophage conditioned medium promotes myoblast proliferation (Cantini et al. 1994; Massimino et al. 1997; Caroleo et al. 2001 ;
Cantini et al. 2002; Chazaud et al. 2003; Tidball, 2005). BB13 cells were used for myoblast expression profiling, since they are a 95-100% pure myoblast population. A monocyte/macrophage cell line (ATCC CRL-9855) was also used to study macrophage expression. The ligands of myoblast receptors were also
surveyed. Primer for each of these genes were found in the scientific literature and synthesized.
Table 6 : Primers sequences for myoblast receptors, ligands and muscle- specific genes.
Cellular RNA was 1) purified with TRIzol®(Gibco 15596), 2) reverse transcribed and 3) amplified. 1) RNA isolation was done according to the manufacturer instructions (GIBCO). Briefly, 1 E6 cells were mixed with 1 ml of Trizol® and
incubate at room temperature for 5 minutes. Then, 200 μl/mlTrizol® of chloroform was added and mixed vigorously for 15 seconds and incubated 3 minutes at room temperature. The mixture was centrifuged for 15 minutes at 12 000g. The aqueous phase containing RNA was recuperated and 500μl/ml of Trizol™ of isopropanol for 15 seconds was added at room temperature to allow the precipitation of RNA. The mixture was incubated 10 minutes at room temperature and centrifuged at 12 00Og for 10 minutes. The supernatant was removed and rinsed with 1 ml/mlTrizol® of a 75% ethanol/25% distilled H2O solution, agitated on vortex few seconds, and centrifuged 5 minutes at 7 50Og. Then, briefly dry RNA samples were solubilized in distilled H2O (~40 μl). Total RNA was quantified and assayed for purity with a spectrophotometer (Beckman Coulter DU 650), where a minimum ratio
, 6 was considered valuable (samples were diluted 1/200 in TRIS-EDTA). 2) For reverse transcription (RT), a mixture of Oligo dt (2 μl_ at 10μM), 5mM of each dNTPs (2 μl_), RNA (1 μg) and RNAse free water was use to complete volume to 17 μl. The mixture was heated to 65°C for RNA denaturation and cooled on ice. 2 μl of 10X buffer and 1 μl de RT were added. Thermocycling of the samples at 420C for 60 minutes and at 70°C for 15 minutes to inactivate the enzyme complete the RT phase. 3) The mixture for PCR reaction consisted of dNTPs (0,5 μl 25 mM), Taq polymerase (20U/ml), Taq buffer 10X (5 μl), cDNA (2 μl), forward+reverse primers (2 μl each) and deonized, RNAse free water (complete to 50 μl). The cycling conditions were as follow: 1 cycle at 940C for 2 minutes; 35 cycles at 94°C for 30 seconds, annealing temperature for 30 seconds and 72°C for 45 seconds; 1 cycle at 72°C for 10 minutes; 1 cycle at 4°C for an indefinite period. Finally, the amplicons were run on agarose gels to evaluate their concentration and their approximate molecular weight.
Statistics. Calculations were performed using Matlab software and a p-value of 0.05 was deemed sufficient to recognize a significant effect.
EXAMPLE Il - COMPARISON OF SEVEN DIFFERENT CULTURE MEDIA
The capacity of seven different culture media to support myoblast expansion was compared with second passage (P2) H49 cells. The cells were cultured as
described in Example I and were inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500 μL/well). Cells were cultured in either i) STD medium, or ii) a first generation serum-free medium developed in our lab (MBa, composition described in Table 7) without any other addittives, or additioned with either iii) a macrophage conditioned medium (obtained from the supernatant of a macrophage culture (ATCC CRL-9855) in DMEM supplemented with ITS, 48 hours following a stimulation with LPS), iv) IL-1α, v) IL-1 β, vi) calpeptine or vii) with a combination of B27 (refer to Table 8 below), N2 and sonic hedgehog (ShH). As shown in Fig. 1 , at culture day nine, four additives (MCM, IL-1α, IL- 1 β, or a combination of B27, N2 and ShH) significantly improved the proliferation of myoblasts compared to MBa alone. However, calpeptine appeared to act as a proliferation/expansion inhibitor.
Table 7 : Composition of MBa medium
Table 8 : Composition of B27 (Brewer et al. 1993)
SERUM-FREE MEDIA
LOBSFM was compared to a serum-free medium commercially available from Lonza (SkGM® +BulletKit®) and with the standard medium (STD). BB13 cells in P4 were cultured as described in Example I. The cells were inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500μL/well) and cultured in either standard medium, SkGM® serum-free medium completed with the BulletKit™ additives, LOBSFM serum-free medium or SkGM® serum-free medium completed with LOBSFM additives. The cell were counted with a hemacytometer at three and five days post-plating. As shown in Fig. 2, cell expansions in the standard medium or in the LOBSFM serum-free medium are similar. However, the expansion of cells in the completed SkGM® serum-free medium or in the SkGM® medium with LOBSFM additives is less important than in the standard medium or in the LOBSFM medium.
EXAMPLE IV - COMPARISON OF LONG TERM EXPANSION OF CELLS IN STANDARD AND SERUM-FREE MEDIA
The reproducibility of long term myoblast proliferation in the LOBSFM and the STD medium was also determined. BB13 cells in P4 were cultured as described in Example I. The cells were trypsinized and inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500 μL/well) at a concentration of 10 000 cells/ml. The results shown in Fig. 3 represent two experiments carried out independently. The monitoring of cellular expansion accounts for the subsequent dilution of the culture, and is therefore expressed in expansion fold.
As shown in Fig. 3, there is no statistical difference between cell expansions in
STD medium or LOBSFM medium.
EXAMPLE V - COMPARISON OF MYOBLAST SPECIFIC ANTIGEN AND
GENE EXPRESSIONS FOR CELLS CULTURED IN STANDARD AND SERUM-FREE MEDIUM
In order to verify that the LOBSFM medium allowed the specific expansion of myoblasts, desmin and NKH-expression was imaged using antibodies. The expression of myoblast-specific antigen was performed on purified and non- purified myoblasts.
As shown in Fig. 4 A to C and 5, the proportion of BB13 cells cultured in the LOBSFM serum-free medium that expressed detectable levels of desmin diminished progressively during the culture. This reduction in desmin expression was more pronounced for non-purified myoblasts (such as H49 and H51 cells, Fig. 5 B) than for purified myoblasts (BB13 cells, Fig. 5 A). In comparison, most of myoblasts cultured in the STD medium maintained high levels of desmin expression, for an extended culture period (six weeks, Fig. 4 I and Fig. 5). Nevertheless, when transferred in a differentiation medium, both BB13 cells expanded in STD medium or LOBSFM fused and expressed desmin similarly (Fig. 4 B and E). This result indicates that culture in the LOBSFM medium does not alter the ability of the cells to differenciate to myotubes.
As shown on Fig. 4 G and H, BB13 cells first cultured in the STD medium fused efficiently when transferred to the differentiation medium (Fig. 4 G and H). In comparison to cells cultured in the STD medium, BB13 cells first cultured for 25 days in the LOBSFM showed similar, or even higher, ability to form myotubes and fuse (Fig. 7). These results indicate that the LOBSFM medium supports the expansion/proliferation of myoblasts while maintaining their myogenic potential, even though desmin expression can decrease during culture.
Myoblasts cultured for four weeks in LOBSFM or STD medium exhibited similar proportion of NKH-1 expressing BB13 cells (Fig. 6 A). However, although the expression levels were similar for BB13 cells, it was lower for non-purified H49 cells cultured in LOBSFM (Fig. 6 B).
Without wishing to be bound to theory, Applicant has hypothesized that this loss in desmin expression during culture could be caused by two phenomena: 1) the medium supports the proliferation of cells other than myoblasts or 2) certain cells can dedifferentiate during the culture. As indicated above, BB13 cells form
a rather uniform population and express initially 95-100% desmin positive. Although phenomenon 1 can be observed during expansion of unpurified biopsies, it would be most unlikely in this case when culturing BB13 cells. Rather, it is most likely that BB13 cells dedifferentiate during culture in the LOBSFM. This dedifferentiate phenomenon has already been reported for other culture. For example, it was observed that the CNTF (ciliary neurotrophic factor) allowed myoblast clones (desmin+) to form multipotent progenitors, having a self-renewal capacity and being able to form several cellular types, in particular neurons, smooth muscles cells and adipocytes. These cells proliferated during more than 20 passages without expressing the muscle regulatory factor (MRF) and it was possible to differentiate them back to the myogenic lineage afterward (Chen et al. 2005). In addition, it is also been shown that IL-1 β blocked myogenin expression and the synthesis of several other proteins (Broussard et al. 2004). Finally, it was previously reported that TWEAK decreases not only the expression of myogenin and MyoD, but also of the actin filaments (Girgenrath et al. 2006). Consequently, the reduction of a marker expression during a culture, such as observed here for desmin in LOBSFM-cultured myoblasts, is not necessarily indicative of a loss in myogenesis capacity. The most important test for testing the functionality of myoblasts is a functional fusion in vitro assay to determine the potential of the cells to fuse together to form myotubes or a functional in vivo fusion assay in DMD patients. The added benefit of the in vitro assay is that it can be performed rapidly as a routine assay and is a good indicator of the in vivo situation.
The expression of several genes, specific or not for myoblasts, has also been quantified by RT-PCR as described in Example I. The RNA of P3 BB13 cells cultured in STD medium for one passage has been isolated with TRIzol®. The intensity of the RT-PCR product staining on an agarose gel has been listed in
Table 9. The results obtained were used to select potential factors to be tested as additives, as well as interpret proliferation assay results previously presented.
Table 9 : List of genes detected by RT-PCR and classified according to the bands on the agarose gel
EXAMPLE Vl - COMPARISON OF INITIAL SEEDING DENSITY AND LAG PHASE FOR CELLS CULTURED IN STANDARD AND SERUM-FREE
MEDIUM
In order to determine the minimal initial seeding cell density required to avoid a cell culture lag phase, P4 BB13 cells were trypsinized and inoculated in 6-well plasma treated plates (Sarstedt 83.1839, 2 ml/well) at a concentration of either 2 000, 10 000 or 40 000 cells/ml in STD medium or LOBSFM. Cells were counted on the fifth day of culture. As shown in Fig. 8, the minimal initial cell concentration of 10 000 cell/ml allowed the culture to grow at a rate similar to the higher initial cell density No statistical difference in the results obtained with the two culture media (STD and LOBSFM) was observed.
EXAMPLE VII - COMPARISON OF A FREEZE/THAW CYCLE ON THE
GROWTH OF CELLS CULTURED IN SERUM-FREE MEDIUM
In order to determine the effect of LOBSFM freezing on cell growth, P4 BB13 were trypsinised and inoculated in 24-well plasma treated plates (Sarstedt 83.1836, 500μL/well) at an initial density of 10 000 cells/ml in either fresh STD
medium or LOBSFM, or LOBSFM that has been frozen at -20 0C overnight, and then thawed. As shown in Fig. 9, a previously frozen LOBSFM does not significantly impact its capacity to expand myoblasts.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
REFERENCES
Adams, V., B. Nehrhoff, et al. (2002). "Induction of iNOS expression in skeletal muscle by IL-1 beta and NFkappaB activation: an in vitro and in vivo study." Cardiovasc Res 54(1 ): 95-104.
Allen, D. L., D. H. Teitelbaum, et al. (2003). "Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro." Am J Physiol Cell Physiol 284(4): C805-15.
Austin, L., J. Bower, et al. (1992). "Effects of leukaemia inhibitory factor and other cytokines on murine and human myoblast proliferation." J Neurol Sci 112(1-2): 185-91.
Belles-Isles, M., R. Roy, et al. (1993). "Rapid selection of donor myoblast clones for muscular dystrophy therapy using cell surface expression of NCAM." Eur J Histochem 37(4): 375-80.
Bogdanovich, S., K. J. Perkins, et al. (2004). "Therapeutics for Duchenne muscular dystrophy: current approaches and future directions." J MoI Med 82(2): 102-15.
Brewer, G. J., J. R. Torricelli, et al. (1993). "Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination." J Neurosci Res 35(5): 567-76.
Broussard, S. R., R. H. McCusker, et al. (2004). "IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts." J Immunol 172(12): 7713-20.
Butler, M. (1991). Mammalian cell biotechnology, a practical approach, Oxford University Press.
Cantini, M., E. Giuhsato, et al. (2002). "Macrophage-secreted myogenic factors: a promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo." Neurol Sci 23(4): 189-94.
Cantini, M., M. L. Massimino, et al. (1994). "Macrophages regulate proliferation and differentiation of satellite cells." Biochem Biophys Res Commun 202(3): 1688-96.
Caroleo, M. C1 N. Costa, et al. (2001). "Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors." J Neuroimmunol 113(2): 193-201.
Carpenter, S., G. Karpati, et al. (1990). "Dystrophin is localized to the plasma membrane of human skeletal muscle fibers by electron-microscopic cytochemical study." Muscle Nerve 13(5): 376-80.
Charge, S. B. and M. A. Rudnicki (2004). "Cellular and molecular regulation of muscle regeneration." Physiol Rev 84(1): 209-38.
Chazaud, B., C. Sonnet, et al. (2003). "Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth." J Cell Biol 163(5): 1133-43.
Chen, M., H. J. Li, et al. (1992). "Dystrophin cytochemistry in mdx mouse muscles injected with labeled normal myoblasts." Cell Transplant 1(1): 17-22.
Chen, X., Z. Mao, et al. (2005). "Dedifferentiation of adult human myoblasts induced by ciliary neurotrophic factor in vitro." MoI Biol Cell 16(7): 3140-51.
Chevrel, G., C. Granet, et al. (2005). "Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors." Ann Rheum Dis 64(9): 1257-62.
Cooper, G. and R. Hausman (2007). The cell a molecular approach, Sinauer Associates, Inc. (a completer)
Davis, J. M. (2002). Basic cell culture: a practical approach, Oxford University Press, 408 pages.
Emery, A., Muntoni, F. (2003). Duchenne muscular dystrophy, Oxford University Press, 282 pages.
Ferrara, N., H. P. Gerber, et al. (2003). "The biology of VEGF and its receptors." Nat Med 9(6): 669-76.
Fitzgerald, K. A., L. A. J. O'Neill, et al. (2001). The cytokine FactsBook. Dundee, Scotland, Academic Press.
Floss, T., H. H. Arnold, et al. (1997). "A role for FGF-6 in skeletal muscle regeneration." Genes Dev 11 (16): 2040-51.
Freshney, R. I. (2000). Culture of Animal Cell: A Manual of Basic Technique. New York, Wiley-Liss.
Freshney, R. I. (2005). Culture of animal cells, a manual of basic technique, Wiley-Liss.
Girgenrath, M., S. Weng, et al. (2006). "TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration." Embo J 25(24): 5826-39.
Goto, S., K. Miyazaki, et al. (1999). "Serum-free culture conditions for analysis of secretory proteinases during myogenic differentiation of mouse C2C12 myoblasts." Anal Biochem 272(2): 135-42.
Gussoni, E., G. K. Pavlath, et al. (1992). "Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation." Nature 356(6368): 435-8.
Ham, R. G. and W. L. McKeehan (1979). "Media and growth requirements." Methods Enzymol 58: 44-93.
Ham, R. G., J. A. St Clair, et al. (1988). "Improved media for normal human muscle satellite cells: serum-free clonal growth and enhanced growth with low serum." In Vitro Cell Dev Biol 24(8): 833-44.
Hancock, J. (2005). "Cell signalling." Oxford University Press: 296. (a completer)
Huard, J., J. P. Bouchard, et al. (1992). "Human myoblast transplantation: preliminary results of 4 cases." Muscle Nerve 15(5): 550-60.
Huard, J., S. Verreault, et al. (1994). "High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice." J Clin Invest 93(2): 586-99.
Jayme, D. W., D. A. Epstein, et al. (1988). "Fetal bovine serum alternatives." Nature 334(6182): 547-8.
John B. Kurek, J. J. B., Jason D. White, Catriona M. Muldoon and and L. Austin (1998). "Leukaemia Inhibitory Factor and Other Cytokines as Factors Influencing Regeneration of Skeletal Muscle." Basic Appl. Myol. 8((5)): 347-360.
Kahn, J. (2006). "Myoblast cell therapy shows promise, but safety issues linger." J Interv Cardiol 19(4): 302-3.
Kinoshita, I., J. T. Vilquin, et al. (1995). "Pretreatment of myoblast cultures with basic fibroblast growth factor increases the efficacy of their transplantation in mdx mice." Muscle Nerve 18(8): 834-41.
Lafreniere, J. F., P. Mills, et al. (2004). "Growth factors improve the in vivo migration of human skeletal myoblasts by modulating their endogenous proteolytic activity." Transplantation 77(11): 1741-7.
Langen, R. C, J. L. Van Der Velden, et al. (2004). "Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization." Faseb J 18(2): 227-37.
Lewin, B., L. Cassimeris, et al. (2007). Cells, Jones and Bartlett.
Li, Y. P. (2003). "TNF-alpha is a mitogen in skeletal muscle." Am J Physiol Cell Physiol 285(2): C370-6.
Massimino, M. L., E. Rapizzi, et al. (1997). "ED2+ macrophages increase selectively myoblast proliferation in muscle cultures." Biochem Biophys Res Commun 235(3): 754-9.
Mather, J. P., Barnes, D. (1998). Animal cell culture methods, Volume 57, Elsevier science and technology, 368 pages.
Miller, K. J., D. Thaloor, et al. (2000). "Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle." Am J Physiol Cell Physiol 278(1): C174-81.
Mizel, S. B. (1989). "The interleukins." Faseb J 3(12): 2379-88.
Muntoni, F., S. Brown, et al. (2002). "Muscle development genes: their relevance in neuromuscular disorders." Neuromuscul Disord 12(5): 438-46.
Naomoto, Y., T. Yamatsuji, et al. (2005). "Rational role of amino acids in intestinal epithelial cells (Review)." lnt J MoI Med 16(2): 201-4.
Nomura, T., E. Ashihara, et al. (2007). "Therapeutic potential of stem/progenitor cells in human skeletal muscle for cardiovascular regeneration." Curr Stem Cell Res Ther 2(4): 293-300.
Omenn, G. S., D. J. States, et al. (2005). "Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database." Proteomics 5(13): 3226-45.
Schlessinger, J. and A. Ullrich (1992). "Growth factor signaling by receptor tyrosine kinases." Neuron 9(3): 383-91.
Skuk, D., M. Goulet, et al. (2006). "Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells." J Neuropathol Exp Neurol 65(4): 371-86.
Skuk, D., M. Goulet, et al. (2007). "First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up." Neuromuscul Disord 17(1): 38-46.
Skuk, D. and J. P. Tremblay (2000). "Progress in myoblast transplantation: a potential treatment of dystrophies." Microsc Res Tech 48(3-4): 213-22.
Skuk, D., J. T. Vilquin, et al. (2002). "Experimental and therapeutic approaches to muscular dystrophies." Curr Opin Neurol 15(5): 563-9.
Strle, K., S. R. Broussard, et al. (2004). "Proinflammatory cytokine impairment of insulin-like growth factor l-induced protein synthesis in skeletal muscle myoblasts requires ceramide." Endocrinology 145(10): 4592-602.
Tidball, J. G. (2005). "Inflammatory processes in muscle injury and repair." Am J Physiol Regul lntegr Comp Physiol 288(2): R345-53.
Torrente, Y., E. El Fahime, et al. (2003). "Tumor necrosis factor-alpha (TNF- alpha) stimulates chemotactic response in mouse myogenic cells." Cell Transplant 12(1): 91-100.
Totsuka, T. (1987), "Centronucleated Myofibers Having Also Peripheral Nuclei in Rectus Femoris Muscles of Muscular Dystrophic Mice". Cong Anom 27: 51- 60.
Voisin, V. and S. de Ia Porte (2004). "Therapeutic strategies for Duchenne and Becker dystrophies." lnt Rev Cytol 240: 1-30.
Whang, X., Z. Bi et al. (2005). "IL-1 receptor antagonist attenuates MAP kinase/AP-1 activation and MMP1 expression in UVA-irradiated human fibroblasts induced by culture medium from UVB-irradiated human skin keratinocytes". lnt J MoI Med 16(6):1117-24.
White, J. D., M. Davies, et al. (2001). "Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: combined in vivo and in vitro studies in post-natal skeletal muscle." Cell Tissue Res 306(1): 129-41.
Yiou, R., L. Zini, et al. (2004). "Therapie cellulaire de I'insuffisance sphincterienne uretrale par autogreffe de cellules precurseur musculaire." Progres en Urologie(14): 93-99.
Zimmerman, A. M., J. L. Vierck, et al. (2000). "Formulation of a defined medium to maintain cell health and viability in vitro." Methods Cell Sci 22(1): 43-9.
Claims
1. A culture medium for a cell of the myogenic lineage, said culture medium comprising:
• a basal medium; and
• a cytokine;
wherein the culture medium is free of serum and allows the proliferation of the cell of the myogenic lineage at a similar rate than another cell of the myogenic lineage cultured in a standard medium containing serum.
2. The culture medium of claim 1 , wherein the cell of the myogenic lineage retains its ability to differentiate after being cultured in the medium.
3. The culture medium of claim 1 , wherein the cell of the myogenic lineage is at least one of a muscular stem cell, a myoblast and a myoblast- derived cell.
4. The culture medium of claim 3, wherein the muscular stem cell can differentiate into a myoblast.
5. The culture medium of claim 3, wherein the myoblast-derived cell is at least one of a muscle cell, a satellite cell and a myocyte.
6. The culture medium of claim 1 , wherein the cell of the myogenic lineage is derived from a biopsy.
7. The culture medium of claim 1 , wherein the cell of the myogenic lineage is a mammalian cell.
8. The culture medium of claim 1 , wherein the cell of the myogenic lineage is a human cell.
9. The culture medium of claim 1 , wherein the basal medium is at least one of Dulbecco's modified Eagles's medium (DMEM), advanced DMEM, Biogro™, SkGM™, Ham's F10, Ham's F12, Iscove's modified Dulbecco's medium, neurobasal medium, RPMI 1640 and MCDB120 medium.
10. The culture medium of claim 1 , wherein the basal medium is a combination of Ham's F12, RPMI 1640 and MCDB120.
11. The culture medium of claim 10, wherein the proportion of Ham's F12, RPMI 1640 and MCDB120 is about 1 :1 :1.
12. The culture medium of claim 1 , wherein the cytokine is a human cytokine.
13. The culture medium of claim 1 , wherein the cytokine is a recombinant cytokine.
14. The culture medium of claim 1 , wherein the cytokine is at least one of a growth factor (GF) and an interleukin.
15. The culture medium of claim 14, wherein the growth factor is at least one of a fibroblast growth factor (FGF), an epidermal growth factor (EGF) and an insulin-like growth factor (IGF).
16. The culture medium of claim 15, wherein the concentration of FGF in the culture medium is between about 1 and 20 ng/ml.
17. The culture medium of claim 15, wherein the FGF is at least one of FGF- 1 , FGF-2, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8 and FGF-9.
18. The culture medium of claim 15, wherein the concentration of EGF in the culture medium is between about 1 and 20 ng/ml.
19. The culture medium of claim 15, wherein the concentration of IGF in the culture medium is between about 1 and 50 ng/ml.
20. The culture medium of claim 15, wherein the IGF is at least one of IGF-1 and IGF-2.
21. The culture medium of claim 14, wherein the concentration of interleukin in the culture medium is between about 0.1 to 20 ng/ml.
22. The culture medium of claim 14, wherein the interleukin is at least one of IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 , IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21 , IL-22, IL-23, IL-24, IL- 25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31 , IL-32 and IL-33.
23. The culture medium of claim 1 , further comprising a supplement.
24. The culture medium of claim 23, wherein the supplement is at least one of:
• a combination of insulin, transferring and selenite (ITS);
• B27;
• a combination of dexamethasone, insulin, EGF, fetuin and albumin; and
• a combination of dexamethasone, bFGF, albumin and insulin.
25. The culture medium of claim 24, wherein the concentration of ITS in the culture medium is between about 0.5 and 2.5% v/v.
26. The culture medium of claim 1 , further comprising a lipid.
27. The culture medium of claim 26, wherein the lipid is at least one of arachidonic acid, cholesterol, DL-α-tocopherol acetate, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitoleic acid, palmitic acid and stearic acid.
28. The culture medium of claim 26, wherein the concentration of the lipid in the culture medium is between about 0.5 and 2.5% v/v.
29. The culture medium of claim 1 , wherein the basal medium is a combination of Ham's F12, RPMI 1640 and MCDB120, wherein the cytokine is a combination of bFGF, FGF4, EGF, IGF1 , IL-1α and IL-I b and wherein said culture medium also comprises bovine serum albumin, fetuin, fibronectin, dexamethasone, insulin, transferrin, selenite, a lipid and B27.
30.An in vitro method of culturing a cell of the myogenic lineage, said method comprising contacting the cell of the myogenic lineage with the culture medium of any one of claims 1 to 29, thereby culturing said cell.
31. The in vitro method of claim 30, wherein the cell of the myogenic lineage is at least one of a muscular stem cell, a myoblast and a myoblast- derived cell.
32. The in vitro method of claim 30, wherein the muscular stem cell can differentiate into a myoblast.
33. The in vitro method of claim 32, wherein the myoblast-derived cell is at least one of a muscle cell, a satellite cell and a myocyte.
34. The in vitro method of claim 30, wherein the method is performed for at least an hour.
35. The in vitro method of claim 30, wherein the method is performed for at least a day
36. The in vitro method of claim 30, wherein the method is performed for at least a week
37. The in vitro method of claim 30, wherein the method is performed for at least a month.
38. The in vitro method of claim 30, wherein said method reduces the lag phase of the cell of the myogenic lineage with respect to the lag phase of a cell of the myogenic lineage cultured in another serum-free media.
39. The in vitro method of claim 30, wherein said method enables the long term expansion of the cell of the myogenic lineage.
40. The in vitro method of claim 30, wherein the initial concentration of the cell of the myogenic lineage in the culture medium is 10 000 cells/mL.
41. The in vitro method of claim 30, the method enables the cell of the myogenic lineage to retain its ability to form a myotube.
42.A method of treating or alleviating a muscular deficiency in a subject in need thereof, said method comprising:
i. contacting a cell of the myogenic lineage with the culture medium of any one of claims 1 to 29; and
ii. implanting the cell of step a) in the subject;
thereby treating or alleviating the muscular deficiency in the subject.
43.A method of treating or alleviating a muscular deficiency in a subject in need thereof, said method comprising:
• providing a cell of the myogenic lineage cultured by the method of any one of claims 30 to 41 ;
• implanting the cell of step a) in the subject; thereby treating or alleviating the muscular deficiency in the subject.
44. The method of claim 42 or 43, wherein the subject is a human.
45. The method of claim 42 or 43, wherein the muscular deficiency is at least one of Duchenne muscular dystrophy, myocardial infarction and urethral sphincter insufficiency.
46. Use of a cell of the myogenic lineage cultured in the culture medium of any one of claims 1 to 29 or prepared by the method of any one of claims 30 to 41 for the treatment or the alleviation of symptoms of a muscular deficiency in a subject.
47. The use of claim 46, wherein the subject is a human.
48. The use of claim 46, wherein the muscular deficiency is at least one of Duchenne muscular dystrophy, myocardial infarction, urethral sphincter insufficiency.
49.A cell of the myogenic lineage cultured in the culture medium of any one of claims 1 to 29 or prepared by the method of any one of claims 30 to 41 for the treatment or the alleviation of symptoms of a muscular deficiency in a subject.
50. The cell of claim 49, wherein the subject is a human.
51. The cell of claim 49, wherein the muscular deficiency is at least one of Duchenne muscular dystrophy, myocardial infarction and urethral sphincter insufficiency.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/120,141 US9139814B2 (en) | 2008-09-22 | 2009-09-22 | Culture medium for myoblasts, precursors thereof and derivatives thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9896408P | 2008-09-22 | 2008-09-22 | |
US61/098,964 | 2008-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010031190A1 true WO2010031190A1 (en) | 2010-03-25 |
Family
ID=42039060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2009/001342 WO2010031190A1 (en) | 2008-09-22 | 2009-09-22 | Culture medium for myoblasts, precursors thereof and derivatives thereof |
Country Status (2)
Country | Link |
---|---|
US (1) | US9139814B2 (en) |
WO (1) | WO2010031190A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102703385A (en) * | 2012-06-26 | 2012-10-03 | 亚太干细胞科研中心有限公司 | A kind of mesenchymal stem cell culture medium |
US20130004466A1 (en) * | 2011-06-14 | 2013-01-03 | Tremblay Jacques P | Myogenic differentiation of stem cells and and uses thereof |
EP2830711A4 (en) * | 2012-03-30 | 2015-08-26 | Univ Central Florida Res Found | METHODS AND COMPOSITIONS USING FGF-9 TO ENHANCE NEOVASCULARIZATION AND REGENERATION |
KR20160085571A (en) * | 2015-01-08 | 2016-07-18 | 이화여자대학교 산학협력단 | A method for differentiation of tonsil-derived mesenchymal stem cell into muscle cells |
WO2016137400A1 (en) * | 2015-02-25 | 2016-09-01 | Agency For Science, Technology And Research | Methods and compositions for expansion and differentiation of skeletal muscle stem cells or progenitor cells |
WO2017196175A1 (en) * | 2016-05-12 | 2017-11-16 | Erasmus University Medical Center Rotterdam | A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium. |
CN112708591A (en) * | 2020-12-24 | 2021-04-27 | 南京农业大学 | Culture medium with definite chemical components for in-vitro differentiation of muscle stem cells |
WO2021158103A1 (en) * | 2020-02-03 | 2021-08-12 | Mosa Meat B.V. | Serum-free medium for culturing a bovine progenitor cell. |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150301067A1 (en) * | 2012-11-05 | 2015-10-22 | University Of Washington Through Its Center For Commercialization | Methods and assays for facioscapulohumeral muscular dystrophy |
JP6890553B2 (en) * | 2015-06-11 | 2021-06-18 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois | Treatment of muscular dystrophy chimeric cells and muscular dystrophy |
AU2018271982B2 (en) * | 2017-05-24 | 2025-05-29 | President And Fellows Of Harvard College | Satellite cells and compositions and methods for producing the same |
CN112553147B (en) * | 2020-12-17 | 2023-07-18 | 江南大学 | A growth factor composition for promoting the proliferation of muscle stem cells and its application |
CN114752554B (en) * | 2022-01-14 | 2023-06-13 | 江南大学 | A kind of serum-free myogenic differentiation medium containing natural compound and its application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990015863A1 (en) * | 1989-06-13 | 1990-12-27 | The Board Of Directors Of The Leland Stanford Junior University | Isolation growth and differentiation of human muscle cells |
US5143842A (en) * | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
US20060057124A1 (en) * | 2004-08-26 | 2006-03-16 | Shim Winston S N | Methods and compositions for culturing cardiomyocyte-like cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2045630A1 (en) * | 1989-11-24 | 1991-05-25 | Lawrence Austin | Proliferative action of leukaemia inhibitory factor on satellite cells |
-
2009
- 2009-09-22 WO PCT/CA2009/001342 patent/WO2010031190A1/en active Application Filing
- 2009-09-22 US US13/120,141 patent/US9139814B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143842A (en) * | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
WO1990015863A1 (en) * | 1989-06-13 | 1990-12-27 | The Board Of Directors Of The Leland Stanford Junior University | Isolation growth and differentiation of human muscle cells |
US20060057124A1 (en) * | 2004-08-26 | 2006-03-16 | Shim Winston S N | Methods and compositions for culturing cardiomyocyte-like cells |
Non-Patent Citations (9)
Title |
---|
BROUSSARD, SR ET AL.: "IL-lbeta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts.", JOURNAL OF IMMUNOLOGY, vol. 172, 15 June 2004 (2004-06-15), pages 7713 - 7720 * |
CANTINI, M ET AL.: "Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 216, 2 November 1995 (1995-11-02), pages 49 - 53 * |
CANTINI, M ET AL.: "Macrophage-secreted myogenic factors: a promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo.", NEUROLOGICAL SCIENCES: OFFICIAL JOURNAL OF THE ITALIAN NEUROLOGICAL SOCIETY AND OF THE ITALIAN SOCIETY OF CLINICAL NEUROPHYSIOLOGY., vol. 23, October 2002 (2002-10-01), pages 189 - 194 * |
CHAKRAVARTHY, MV ET AL.: "IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle.", JOURNAL OF APPLIED PHYSIOLOGY., vol. 89, October 2000 (2000-10-01), pages 1365 - 1379 * |
DAS, M ET AL.: "A defined system to allow skeletal muscle differentiation and subsequent integration with silicon microstructures.", BIOMATERIALS., vol. 27, August 2006 (2006-08-01), pages 4374 - 4380 * |
GOTO, S ET AL.: "Serum-free culture conditions for analysis of secretory proteinases during myogenic differentiation of mouse C2C12 myoblasts.", ANALYTICAL BIOCHEMISTRY., vol. 272, August 1999 (1999-08-01), pages 135 - 142 * |
LECOEUR, C ET AL.: "Intraurethral transfer of satellite cells by myofiber implants results in the formation of innervated myotubes exerting tonic contractions.", THE JOURNAL OF UROLOGY., vol. 178, July 2007 (2007-07-01), pages 332 - 337 * |
SKUK, D ET AL.: "Dystrophin expression in muscles ofDuchenne muscular dystrophy patients after high-density injections of normal myogenic cells.", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY., vol. 65, April 2006 (2006-04-01), pages 371 - 386 * |
ZIMMERMAN, AM ET AL.: "Formulation of a defined medium to maintain cell health and viability in vitro.", METHODS IN CELL SCIENCE., vol. 22, March 2000 (2000-03-01), pages 43 - 49 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130004466A1 (en) * | 2011-06-14 | 2013-01-03 | Tremblay Jacques P | Myogenic differentiation of stem cells and and uses thereof |
US8900572B2 (en) * | 2011-06-14 | 2014-12-02 | UNIVERSITé LAVAL | Myogenic differentiation of stem cells and uses thereof |
EP2830711A4 (en) * | 2012-03-30 | 2015-08-26 | Univ Central Florida Res Found | METHODS AND COMPOSITIONS USING FGF-9 TO ENHANCE NEOVASCULARIZATION AND REGENERATION |
CN102703385A (en) * | 2012-06-26 | 2012-10-03 | 亚太干细胞科研中心有限公司 | A kind of mesenchymal stem cell culture medium |
KR20160085571A (en) * | 2015-01-08 | 2016-07-18 | 이화여자대학교 산학협력단 | A method for differentiation of tonsil-derived mesenchymal stem cell into muscle cells |
KR101642637B1 (en) | 2015-01-08 | 2016-07-25 | 이화여자대학교 산학협력단 | A method for differentiation of tonsil-derived mesenchymal stem cell into muscle cells |
WO2016137400A1 (en) * | 2015-02-25 | 2016-09-01 | Agency For Science, Technology And Research | Methods and compositions for expansion and differentiation of skeletal muscle stem cells or progenitor cells |
CN107406827A (en) * | 2015-02-25 | 2017-11-28 | 新加坡科技研究局 | Methods and compositions for expansion and differentiation of skeletal muscle stem cells or skeletal muscle progenitor cells |
EP3262158A4 (en) * | 2015-02-25 | 2018-08-15 | Agency For Science, Technology And Research | Methods and compositions for expansion and differentiation of skeletal muscle stem cells or progenitor cells |
US20180245048A1 (en) * | 2015-02-25 | 2018-08-30 | Agency For Science, Technology And Research | Methods and compositions for expansion and differentiation of skeletal muscle stem cells or progenitor cells |
WO2017196175A1 (en) * | 2016-05-12 | 2017-11-16 | Erasmus University Medical Center Rotterdam | A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium. |
WO2021158103A1 (en) * | 2020-02-03 | 2021-08-12 | Mosa Meat B.V. | Serum-free medium for culturing a bovine progenitor cell. |
US20230083026A1 (en) * | 2020-02-03 | 2023-03-16 | Mosa Meat B.V. | Serum-free medium for culturing a bovine progenitor cell |
CN112708591A (en) * | 2020-12-24 | 2021-04-27 | 南京农业大学 | Culture medium with definite chemical components for in-vitro differentiation of muscle stem cells |
US20220204923A1 (en) * | 2020-12-24 | 2022-06-30 | Nanjing Joes Future Food Technology Co., Ltd. | Chemically defined medium for differentiation of muscle stem cells in vitro |
Also Published As
Publication number | Publication date |
---|---|
US20110250691A1 (en) | 2011-10-13 |
US9139814B2 (en) | 2015-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9139814B2 (en) | Culture medium for myoblasts, precursors thereof and derivatives thereof | |
CN112322580B (en) | Application of serum-free medium for mesenchymal stem cells | |
Wu et al. | Muscle-derived stem cells: isolation, characterization, differentiation, and application in cell and gene therapy | |
US9388384B2 (en) | Mesenchymal stem cells produced from human pluripotent stem cells | |
AU2020392595B2 (en) | Biomaterials for the prevention and the treatment of tissue disorders | |
US20140315307A1 (en) | Mixed population of cells deriving from adipose tissue and methods of isolating and using the same | |
KR20130112028A (en) | Serum-free chemically defined cell culture medium | |
WO2007061750A2 (en) | Adipose tissue derived stromal cells for the treatment of neurological disorders | |
MX2008016429A (en) | Serum-free media and their uses for chondrocyte expansion. | |
US20170044489A1 (en) | Serum-free medium | |
US20130058903A1 (en) | Stem-Cell Material and Method of Use | |
US20140271616A1 (en) | Compositions And Methods For Mesenchymal And/Or Chondrogenic Differentiation Of Stem Cells | |
KR102679956B1 (en) | Method of culturing muscle cells for producing cattle cultured meat | |
KR20200047330A (en) | Stem cell-derived microvesicles with enhanced efficacy, use thereof and method for enhancing efficacy | |
US20230181647A1 (en) | Treatment of ovarian failure using regenerative cells | |
KR101468123B1 (en) | Compositions for Improving or Treating Muscle Atrophy Diseases Comprising Stem Cells Derived from Umbilical Cord | |
US11351119B2 (en) | Stem cell-derived microvesicles with enhanced efficacy, use thereof, and method for enhancing efficacy | |
JP2007520233A (en) | Compositions and methods for culturing neural stem cells using bone marrow stromal cells | |
KR20190027651A (en) | Sertoli-like cells from stem cells, a method for preparing thereof, and uses thereof | |
WO2020190672A1 (en) | Cardiomyocyte-derived exosomes inducing regeneration of damaged heart tissue | |
Milan et al. | Cell sources in cardiac tissue engineering: current choices | |
KR20110094940A (en) | A method for differentiating mesenchymal stem cells into JB-like neurons and a composition for inducing WB-like neuronal differentiation, including WDN | |
KR20160088839A (en) | A method for differentiation of tonsil-derived mesenchymal stem cell into muscle cells | |
JP2023513618A (en) | Telomere length regulation using fibroblasts | |
CN104120106A (en) | Method of forming skeletal muscle cell by induction differentiation by utilization of pig dedifferentiated adipocyte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09813952 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13120141 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09813952 Country of ref document: EP Kind code of ref document: A1 |